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Abstract
HDL regulation is exerted at multiple levels including regulation at the level of
transcription initiation by transcription factors and signal transduction cascades;
regulation at the posttranscriptional level by microRNAs and other noncoding
RNAs which bind to the coding or noncoding regions of HDL genes regulating
mRNA stability and translation; as well as regulation at the posttranslational
level by protein modifications, intracellular trafficking, and degradation. The
above mechanisms have drastic effects on several HDL-mediated processes
including HDL biogenesis, remodeling, cholesterol efflux and uptake, as well
as atheroprotective functions on the cells of the arterial wall. The emphasis is on
mechanisms that operate in physiologically relevant tissues such as the liver
(which accounts for 80 % of the total HDL-C levels in the plasma), the
macrophages, the adrenals, and the endothelium. Transcription factors that
have a significant impact on HDL regulation such as hormone nuclear receptors
and hepatocyte nuclear factors are extensively discussed both in terms of gene
promoter recognition and regulation but also in terms of their impact on plasma
HDL levels as was revealed by knockout studies. Understanding the different
modes of regulation of this complex lipoprotein may provide useful insights for
the development of novel HDL-raising therapies that could be used to fight
against atherosclerosis which is the underlying cause of coronary heart disease.
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AP1 Activator protein 1






ARP-1 Apolipoprotein A-I-regulated protein 1
DHHC8 Asp-His-His-Cys 8
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
BIG1 Brefeldin A-inhibited guanine nucleotide-exchange protein 1
JNK c-Jun N-terminal kinase
C/EBP CCAAT/enhancer-binding protein
CAV-1 Caveolin 1
CXCL Chemokine (C-X-C motif) ligand
COUP-TFI Chicken ovalbumin upstream promoter transcription factor I
CEH Cholesterol ester hydrolase
CETP Cholesterol ester transfer protein
3C Chromosome conformational capture
CLA Conjugated linoleic acid
CAR Constitutive androstane receptor
CREB Cyclic AMP response element-binding protein
DNase Deoxyribonuclease
DR4 Direct repeat with 4 nucleotides in the spacer region
DBD DNA-binding domain




ESCRT Endosomal sorting complex required for transport
ERα and β Estrogen receptors α and β
ERE Estrogen response element
ESRRG Estrogen receptor-related gamma
FXR Farnesoid X receptor
FXRE Farnesoid X receptor-responsive element
FF Fenofibrate
FOXA2 Forkhead box A2
FOXΟ1 Forkhead box Ο1
GF Gemfibrozil
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GR Glucocorticoid receptor
GSK3β Glycogen synthase kinase 3β
HNF-4 Hepatocyte nuclear factor-4
HDL High-density lipoprotein
HDL-C High-density lipoprotein cholesterol
Hcy Homocysteine
HRE Hormone response element
IRAK-1 IL-1 receptor-associated kinase 1




KLF4 Kruppel-like factor 4
LCAT Lecithin-cholesterol acyltransferase
LXR Liver X receptor
LXRE Liver X receptor response element
LRH-1 Liver receptor homologue-1
LBD Ligand-binding domain
LPS Lipopolysaccharide
LDLR Low-density lipoprotein receptor
LAL Lysosomal acid lipase
MCSF Macrophage colony-stimulating factor
miRNAs microRNAs
MEKK Mitogen-activated protein kinase/ERK kinase kinase




NHERF Na+/H+ exchanger regulator factor
NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells
NFY Nuclear factor Y
ORP1S Oxysterol-binding protein-related protein 1S
PDZK1 PDZ domain-containing adaptor protein
PPAR Peroxisome proliferator-activated receptors
PPRE Peroxisome proliferator-activated receptor-responsive element
PMA Phorbol 12-myristate 13-acetate
PI3K phosphatidylinositol 3- kinase
PLD Phospholipase D
PGC-1 PPARgamma coactivator 1
PLTP Phospholipid transfer protein
pri-miRNA Primary long miRNA
PREB Prolactin regulatory element-binding
PEST Proline, glutamic acid, serine, threonine
PKC Protein kinase C
PCA Protocatechuic acid
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PCSK9 Proprotein convertase subtilisin/kexin type 9
RAR Retinoic acid receptor
RORα Retinoic acid receptor-related orphan receptor α
RXRα Retinoid X receptor α
RISC RNA-induced silencing complex
SR-BI Scavenger receptor class B type I
SPTLC1 Serine palmitoyltransferase 1
STAT Signal transducer and activator of transcription
SHP Small heterodimer partner
siRNAs Small interfering RNAs
SP1 Specificity protein 1
S1P Sphingosine 1 phosphate
SRC-1 Steroid receptor coactivator-1
SF-1 Steroidogenic factor-1
SREBP Sterol regulatory element-binding protein
SREs Sterol-responsive elements
TRβ Thyroid hormone receptor β
TAD Transactivation domain
TGFβ1 Transforming growth factor β1
TNFα Tumor necrosis factor α
Tpl2 Tumor progression locus 2
UTR Untranslated region
URE Upstream regulatory element
USF Upstream stimulatory factors
VDR Vitamin D receptor
WT Wild type
YY1 Yin Yang 1
ZIC Zinc finger of the cerebellum
ZNF202 Zinc finger protein 202
1 Regulation of Genes Involved in HDL Metabolism
at the Transcriptional Level
A large body of work generated over the past four decades has revealed that
eukaryotic gene transcription is a remarkably intricate biochemical process that is
tightly regulated at many levels by the ordered assembly of multiprotein transcrip-
tion initiation complexes to specific regulatory regions in the promoters of genes
(Roeder 1998, 2005; Lemon and Tjian 2000). Despite the progress made, still
limited knowledge regarding the details exists. It is believed that specificity in
gene regulation is determined by the unique order of cis-acting regulatory regions
which are recognized by sequence-specific DNA-binding transcription factors.
Recent advances in gene regulation technologies including the powerful chromatin
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immunoprecipitation assay have enabled the monitoring in real time of the ordered
assembly and the disassembly of transcription factor complexes on the promoters
and the enhancers of genes in response to extracellular or intracellular cues
(Christova 2013; Rodriguez-Ubreva and Ballestar 2014). High-throughput
sequencing technologies have revolutionized the fields of genomics, epigenomics,
and transcriptomics and have provided novel insights into the transcription
signatures of human diseases (Churko et al. 2013). Furthermore, using new power-
ful methodologies such as chromosome conformation capture (3C) and its
derivatives, we are at a position to monitor dynamic intra- and interchromosomal
interactions that allow the optimal expression of genes at a given time and space
(Gavrilov et al. 2009; Wei et al. 2013).
Transcription factors may be constitutively active in a cell or work in an
inducible mode in response to various ligands and signal transduction pathways.
The cross talk between different signaling pathways which orchestrate the cellular
responses can be facilitated by the physical and functional interactions between
transcription factors, and these interactions can be monitored by various methods
both in vivo and in vitro. All known transcription factors are modular in nature and
contain a DNA-binding domain and a transcriptional activation domain (Mitchell
and Tjian 1989; Lemon and Tjian 2000). In addition, several factors contain a
dimerization domain that permits them to form homodimers and/or heterodimers. A
variety of nuclear receptors for steroids, thyroids, retinoids, etc. contain a ligand
binding site. Via their transcription activation domains, transcription factors appear
to facilitate the recruitment of the proteins of the coactivator complex and the basal
transcription complex to the transcription initiation site of each gene and thus
initiate transcription (Roeder 2005). Importantly, the activity of transcription
factors can be modulated by drugs against diseases such as cancer and cardio-
vascular disease as exemplified by the drugs that activate or repress the hormone
nuclear receptors (Gronemeyer et al. 2004).
It is beyond the scope of this chapter to provide a thorough review of the
different mechanisms of transcriptional regulation of eukaryotic genes or to
describe extensively the different classes of transcription factors, their structures,
and their mode of regulation. We will only focus on those classes of transcription
factors that have been shown to play key roles in the regulation of the genes
involved in lipid and lipoprotein metabolism and more specifically on those
involved in the metabolism of high-density lipoproteins (HDL) such as the hormone
nuclear receptors.
1.1 General Introduction to Hormone Nuclear Receptors
Hormone nuclear receptors belong to a superfamily of transcription factors that are
activated by steroid hormones (estrogens, androgens, glucocorticoids, etc.),
retinoids, thyroids, and products of intermediate metabolism such as bile acids,
fatty acids, and cholesterol derivatives, among others (Gronemeyer et al. 2004).
Some members of this family do not need ligand binding to regulate transcription
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and are classified as “orphans” (Blumberg and Evans 1998). Nuclear receptors are
structurally highly conserved. In terms of primary structure, the highest degree of
homology among family members is in the DNA-binding domain that contains two
zinc fingers (Helsen et al. 2012). Nuclear receptors also contain two transactivation
domains (TADs), one N-terminal ligand-independent TAD called activation func-
tion 1 (AF1) and a ligand-dependent TAD called AF2 located close to the ligand-
binding domain (LBD) (Rochel et al. 2011). Nuclear receptors bind to hormone
response elements (HREs) on the promoters of target genes either as homodimers or
as heterodimers with the retinoid X receptor (RXR). The HREs consist of direct
repeats (DRs), inverted repeats (IRs), or palindromic repeats (PRs) of the consensus
sequence 50 AG(G/T)TCA 30. The repeats are separated by 1, 2, 3, 4, or
5 nucleotides and are designated DR1, DR2, etc. (for the direct repeats); IR1,
IR2, etc. (for the inverted repeats); and PR1, PR2, etc. (for the palindromic repeats)
as described previously (Kardassis et al. 2007; Helsen et al. 2012). The HRE type
and inter-repeat spacing determine to a large degree the specificity in nuclear
receptor binding, but this rule is not strict at all. For instance, both LXR/RXR
and T3R/RXR heterodimers prefer to bind to DR4 HREs, whereas RAR/RXR
heterodimers bind to DR5. The direct repeats with one base spacing (DR1 type)
appear to be very promiscuous as they bind RXR, COUP-TFI, ARP-1, and HNF-4
homodimers and PPAR/RXR, RAR/RXR, COUP-TFI/RXR, and ARP-1/RXR
heterodimers (Nakshatri and Bhat-Nakshatri 1998). The elucidation of the three-
dimensional structure of the ligand-binding domain of several nuclear receptors by
X-ray crystallography in the absence and in the presence of ligands has allowed a
good understanding of the modulation of nuclear receptor action by ligands and the
development of very potent agonists and antagonists, some of which have been used
therapeutically (Bourguet et al. 2000). Chromatin immunoprecipitation studies
usually reveal that nuclear receptors are constitutively nuclear and bound to chro-
matin but they are transcriptionally silent in the absence of ligand. The binding of
the ligand to the LBD causes a major conformational change to this domain which
culminates in the recruitment of nuclear receptor coactivators such as PGC-1 and
CBP/p300 and the displacement of corepressors (Chen and Li 1998; Liu and Lin
2011). Nuclear receptors can cross talk with other transcription factors in a positive
or a negative manner as exemplified by the negative regulation of Jun or NF-κB
transcription factors by the glucocorticoid receptors during inflammation, a mecha-
nism termed trans-repression (Adcock and Caramori 2001).
1.2 Transcriptional Regulation of the apoA-I Gene in the Liver
The hypothesis that apolipoprotein (apo) A-I overexpression positively influences
plasma concentrations of HDL cholesterol (HDL-C) has been validated experi-
mentally in transgenic mice expressing human apoA-I under homologous or hetero-
logous regulatory sequences. These mice have significantly elevated plasma levels
of HDL-C and human apoA-I (Rubin et al. 1991; Kan et al. 2000). These “humanized”
apoA-I transgenic mice are valuable tools for the study of apoA-I gene regulation
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in vivo. Furthermore, it was demonstrated that the overexpression of apoA-I in apoE
KO or LDLR KO mice via transgene- or adenovirus-mediated gene transfer reduced
atherosclerosis development confirming the anti-atherogenic role of apoA-I
upregulation (Paszty et al. 1994; Belalcazar et al. 2003; Valenta et al. 2006).
In humans, the apoA-I gene is expressed abundantly in the liver and intestine and
to a lesser extent in other tissues (Zannis et al. 1985). Early studies had established
that the human apoA-I promoter containing 250 bp upstream from the transcription
start site of the gene is sufficient to drive liver-specific gene expression both in cell
cultures and in mice (Walsh et al. 1989; Tzameli and Zannis 1996; Hu et al. 2010a).
This promoter region is rich in nuclear factor binding sites and responds to various
intracellular as well as extracellular ligands (Zannis et al. 2001a; Haas and
Mooradian 2010). As shown in Fig. 1, prominent role in the regulation of the
apoA-I promoter play two hormone response elements (HREs) located at positions
210/190 and 132/120 that bind members of the hormone nuclear receptor
superfamily in a competitive manner (Tzameli and Zannis 1996).
One of the nuclear receptors that plays a prominent role in apoA-I gene regu-
lation in the liver and the intestine is the hepatocyte nuclear factor-4 (HNF-4).
HNF-4 was discovered as a rat liver nuclear protein that binds to the promoters
of liver-specific genes such as transthyretin and apolipoprotein C-III (Sladek 1994).
In the adult organism, HNF-4 is expressed in the liver, kidney, intestine, and
pancreas (Sladek 1994). The total disruption of the HNF-4 gene in mice leads to
an embryonic lethal phenotype due to the impairment of endodermal differentiation
and gastrulation (Chen et al. 1994). This early developmental arrest was rescued by
the complementation of the HNF-4α/ embryos with a tetraploid embryo-derived
Fig. 1 Regulatory elements and transcription factors that control the expression of the apoA-I
gene. Arrows and block lines denote activation and repression, respectively. The mechanisms are
described in detail in the text. Abbreviations: retinoic acid receptor (RAR); retinoid X receptor
(RXR); thyroid receptor β (TRβ); farnesoid X receptor (FXR); hepatocyte nuclear factor (HNF);
apoA-I regulatory protein 1 (ARP-1); forkhead box 2 (FOXA2); nuclear factor Y (NFY); CCAAT/
enhancer-binding protein (CEBP); liver receptor homologue-1 (LRH-1); small heterodimer part-
ner (SHP); specificity protein 1 (Sp1); tumor necrosis factor α (TNFα), interleukin-1 (IL-1);
lipopolysaccharide (LPS)
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wild-type visceral endoderm (Li et al. 2000). The analysis of the rescued mice
showed that the expression of the apoA-I gene as well as of other apolipoprotein
genes, shown previously to be regulated by HNF-4 including apoA-II, apoB, apoC-
III, and apoC-II, was abolished confirming the cell culture data (Li et al. 2000).
Experiments in mice in which the HNF-4 gene was disrupted in the adult liver using
Alb-Cre revealed that HNF-4 is essential not only for the establishment but also for
the maintenance of hepatic differentiation status (Hayhurst et al. 2001). Lipid and
lipoprotein analysis of plasma of these mice revealed a dramatic reduction in total
cholesterol, HDL cholesterol, and triglycerides as well as a dramatic increase in the
concentration of bile acids (Hayhurst et al. 2001). Furthermore, FPLC analysis
showed that HDL cholesterol from the HNF-4 Liv KO mice eluted later than that
from controls indicative of the presence of smaller HDL populations. Interestingly,
the expression of the two essential genes for HDL biogenesis, namely apoA-I and
ABCA1, was not affected in the livers of the HNF-4 Liv KO, suggesting that the
reduction in the plasma HDL levels was the result of altered HDL remodeling rather
than reduced biosynthesis. In agreement with this, the expression level of the HDL
receptor SR-BI gene was dramatically increased (Hayhurst et al. 2001).
Studies in transgenic mice expressing the human apoA-I gene under its own
regulatory sequences and clinical studies in humans have shown that fibrates have a
positive effect on apoA-I gene transcription as well as on plasma HDL levels. The
increase in human apoA-I gene transcription by fibrates is mediated by peroxisome
proliferator-activated receptor α (PPARα) which binds to a PPRE on the proximal
apoA-I promoter as a heterodimer with RXRα (Tzameli and Zannis 1996; Staels
and Auwerx 1998). This was confirmed by in vivo experiments performed in mice
that express human apoA-I under the control of its own promoter but lack the
expression of PPARα. When these mice were given fenofibrate (FF) or gemfibrozil
(GF) for 17 days, an increase in plasma HDL-C levels was observed by FF and to a
lesser extent by GF only in the mice that express endogenous PPARα (Duez
et al. 2005). The fibrate-treated mice had larger HDL particles possibly due to the
upregulation of phospholipid transfer protein and downregulation of SR-BI (Duez
et al. 2005). Interestingly, the apoA-I gene cannot be upregulated by fibrates in
rodents due to a three base pair difference in the PPRE rendering the rodent apoA-I
PPRE nonfunctional (Vu-Dac et al. 1994). In line with the above findings, liver-
specific inactivation of the PPARα heterodimer partner retinoid X receptor α
(RXRα) gene in mice was associated with increased expression of the apoA-I
gene (Wan et al. 2000).
In a clinical study involving 234 patients with combined hyperlipidemia, both
FF and GF reduced triglycerides and increased HDL-C to a similar extent, but only
FF treatment increased apoA-I plasma levels, and this was in agreement with the
previous clinical trials (Schaefer et al. 1996; Durrington et al. 1998; Sakai
et al. 2001; Duez et al. 2005).
A humanized apoA-I transgenic mouse model expressing human apoA-I under
its own regulatory sequences in a mouse apoA-I null background was recently used
to identify by global gene expression profiling candidate genes that affect lipid and
lipoprotein metabolism in response to fenofibrate treatment (Sanoudou et al. 2009).
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Bioinformatical analysis and stringent selection criteria (twofold change, 0 % false
discovery rate) identified 267 significantly changed genes. In contrast to the study
by Duez et al. discussed above (Duez et al. 2005), fenofibrates (FF) did not
significantly alter the levels of hepatic human apoA-I mRNA and plasma apoA-I
protein. This could be due to differences either in the mouse models used (for
instance, the humanized apoA-I mouse of Sanoudou et al. has 2.1 kb apoA-I
promoter fragment, whereas the model of Duez et al. has a 5.5 kb apoA-I promoter)
or the doses of fibrates (0.2 % w/w in the paper of Duez et al. and 0.03 % in the
paper by Sanoudou et al.). Despite the lack of apoA-I responsiveness, the FF
treatment increased cholesterol levels 1.95-fold mainly due to the increase in
HDL-C. The observed changes in HDL were associated with the upregulation of
genes involved in phospholipid biosynthesis and lipid hydrolysis, as well as in the
phospholipid transfer protein. The gene encoding the estrogen receptor-related
gamma (ESRRG) transcription factor was upregulated 2.36-fold by FF and had a
significant positive correlation with genes of lipid and lipoprotein metabolism and
mitochondrial functions, indicating an important role of this orphan receptor in
mediating the FF-induced activation of a specific subset of its target genes
(Sanoudou et al. 2009).
In addition to HNF-4 and PPARα, the two HREs of the proximal human apoA-I
promoter bind apoA-I regulatory protein 1 (ARP-1) and liver receptor homologue-1
(LRH-1) which repress and activate the apoA-I promoter, respectively, as illustrated
in Fig. 1 (Ladias and Karathanasis 1991; Delerive et al. 2004). LRH-1 is a member of
the fushi tarazu subfamily of nuclear receptors that is highly expressed in the liver,
intestine, pancreas, and ovary (Fayard et al. 2004). In the liver, LRH-1 plays a key
role in cholesterol homeostasis, through the control of the expression of genes that are
implicated in bile acid biosynthesis and enterohepatic circulation such as CYP7A1,
CYP8B1, and ABCG5/8 (del Castillo-Olivares and Gil 2000; Freeman et al. 2004;
Kir et al. 2012; Back et al. 2013), reverse cholesterol transport (SR-BI, apoA-I)
(Schoonjans et al. 2002; Delerive et al. 2004), and HDL remodeling (CETP) (Luo
et al. 2001). However, mice with targeted inactivation of the LRH-1 gene in the liver
are characterized by physiological levels of HDL cholesterol, LDL cholesterol, and
triglycerides but have a profound effect on bile acid composition in the liver which
leads to reduced intestinal reuptake of bile acids and to the enhanced removal of
lipids from the body (Mataki et al. 2007). Recent data suggest that LRH-1 functions
in a compensatory safeguard mechanism for adequate induction of bile salt synthesis
under conditions of high bile salt loss (Out et al. 2011).
The two HREs of the apoA-I promoter also mediate the response of apoA-I to
thyroids, retinoids, and bile acids via heterodimers of RXRα with thyroid hormone
receptor β (TRβ), retinoic acid receptor α (RARα), and farnesoid X receptor α
(FXRα), respectively (Rottman et al. 1991; Hargrove et al. 1999). Although
retinoids activate apoA-I gene expression, thyroids have dual effects on apoA-I
promoter activity, whereas bile acids inhibit apoA-I gene expression (Taylor
et al. 1996; Tzameli and Zannis 1996; Srivastava et al. 2000; Claudel
et al. 2002). As shown in Fig. 1, in response to bile acids, FXR downregulates
apoA-I gene transcription by two complementary mechanisms: (a) a direct binding
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to the apoA-I HRE and (b) an indirect mechanism via the induction of small
heterodimer partner (Bavner et al. 2005) which, in turn, represses the activity of
LRH-1 (Delerive et al. 2004).
The nuclear receptor constitutive androstane receptor (CAR) regulates the
detoxification of xenobiotics and endogenous molecules. In mice, the specific
CAR agonist 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) decreased
HDL cholesterol and plasma apoA-I levels in a CAR-specific manner (Masson
et al. 2008). In transient transfections, CAR decreased the activity of the human
apoA-I promoter in the presence of TCPOBOP, but the mechanism by which this
repression is facilitated remains unknown (Masson et al. 2008).
Ligands of the vitamin D receptor (VDR) were also shown to affect negatively
apoA-I gene expression in hepatic cells (Wehmeier et al. 2005). In VDR KO mice,
serum HDL-C levels were 22 % higher and the mRNA levels of apoA-I were
49.2 % higher compared with WT mice. The mechanisms by which VDR ligands
affect HDL levels remain unclear (Wang et al. 2009).
1.2.1 The Role of the Distal Enhancer in apoA-I Gene Transcription
In addition to its own promoter, optimal expression of the human apoA-I gene in
hepatic and intestinal cells requires the presence of a 200 bp transcriptional
enhancer element located downstream of the apoA-I gene, 500 bp upstream of
the first exon of the adjacent apoC-III gene. This regulatory region, which
coordinates the expression of all three genes of the apoA-I/C-III/A-IV cluster,
contains two hormone response elements that bind HNF-4 and different
combinations of ligand-dependent nuclear receptors as well as two binding sites
for the ubiquitous transcription factor specificity protein 1 (Sp1) (Kardassis
et al. 1997; Lavrentiadou et al. 1999). The mutagenesis of the HREs and of the
Sp1 sites reduced the activity of the apoA-I promoter/C-III enhancer cassette in cell
cultures and abolished the binding of the corresponding factors (Kardassis
et al. 1997; Lavrentiadou et al. 1999).
The contribution of the HREs and the Sp1 binding sites to the tissue-specific
expression of the apoA-I gene in vivo was addressed using transgenic mice bearing
the WT apoA-I/apoC-III gene cluster under the control of their regulatory regions
or the same cluster bearing mutations in different regulatory elements
(Georgopoulos et al. 2000; Kan et al. 2000, 2004). It was shown that mutations in
one of the two HREs of the enhancer (element I4) abolished the intestinal expres-
sion and reduced the hepatic expression of the adjacent apoA-I gene to 20 % of the
control. Mutations in the two HREs of the proximal apoA-I promoter reduced the
hepatic and intestinal expression of the apoA-I gene to approximately 15 % of the
control, whereas combined mutations in all three HREs totally eliminated the
intestinal and hepatic expression of the apoA-I gene (Kan et al. 2000). Studies in
cell cultures established that HNF-4 and Sp1 factors are both required for the
synergy between the apoA-I promoter and the enhancer by physically interacting
with each other and forming transcriptional complexes in order to facilitate the
recruitment of the basal transcriptional machinery (Kardassis et al. 2002). The
aforementioned mouse model that expresses human apoA-I under its own promoter
Regulation of HDL Genes: Transcriptional, Posttranscriptional, and. . . 123
and enhancer (Kan et al. 2000) is very useful for the in vivo characterization of the
mechanisms that regulate the expression of the apoA-I gene under physiological or
pathological conditions as well as for the identification and validation of novel
compounds that are designed to upregulate human apoA-I gene transcription and
serve as HDL-raising drugs. This is especially important in light of the differences
between the mouse and the human apoA-I promoters. For instance, the mouse gene
cannot be upregulated by fibrates due to a three base pair difference in the PPRE
compared to the human promoter which responds to 0.2 % fibrates but not to 0.03 %
fibrates as mentioned above.
1.2.2 Other Factors Regulating apoA-I Gene Transcription
Further upstream from the two apoA-I HREs, an insulin response core element
(IRCE) was identified and shown to bind Sp1 (Murao et al. 1998). Insulin-activated
signaling pathways including the Ras/raf and the phosphatidylinositol 3-kinase
(PI3K) have been shown to posttranslationally modify Sp1, and this leads to
increased apoA-I promoter activity (Mooradian et al. 2004).
Early growth response protein 1 (EGR-1) is another transcription factor that
regulates apoA-I expression via the proximal HREs (Kilbourne et al. 1995; Cui
et al. 2002). Mice with experimental nephrotic syndrome are characterized by a
fivefold increase in the levels of EGR-1, and these changes were associated with
high plasma apoA-I and HDL-C levels as well as apoA-I gene transcription in the
liver (Zaiou et al. 1998). In line with these findings, mice deficient in EGR-1 have
reduced plasma HDL-C and apoA-I as well as hepatic apoA-I mRNA levels (Zaiou
et al. 1998). EGR-1 was shown to mediate the response of the apoA-I promoter to
estrogens (Hargrove et al. 1999).
The proximal apoA-I promoter also contains one element that binds the basic
leucine zipper (bZip) factor CCAAT/enhancer-binding protein (C/EBP) and
nuclear factor Y (NFY) and another element that binds hepatocyte nuclear factor-
3β/FOXA2 (Papazafiri et al. 1991; Novak and Bydlowski 1997). Nuclear factor
HNF-3β was shown to mediate the response of the apoA-I promoter to
glucocorticoids (Hargrove et al. 1999).
Several natural compounds with antioxidant, pro-estrogenic, or other activities
were shown to affect apoA-I and HDL-C levels, and these studies are summarized
in Haas and Mooradian (2010).
Pro-inflammatory cytokines including tumor necrosis factor α (TNFα) and
interleukin-1β (IL-1β) were previously shown to inhibit apoA-I gene expression
both in cell cultures and in animals (Ettinger et al. 1994; Song et al. 1998).
Furthermore, plasma levels of HDL-C and apoA-I were shown to be highly
increased in mice deficient in the p50 subunit of the pro-inflammatory transcription
factor NF-κB (Morishima et al. 2003). In agreement with this observation, the
activation of NF-κB by lipopolysaccharide (LPS) caused a reduction in apoA-I
mRNA and protein levels in HepG2 cells, whereas the inhibition of NF-κB via
adenovirus-mediated overexpression of IκBα abolished the reduction (Morishima
et al. 2003). This IκBα-induced apoA-I increase was blocked by preincubation with
MK886, a selective inhibitor of peroxisome proliferator-activated receptor α, and
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mutations in the PPARα binding site in the apoA-I promoter abrogated these
changes (Morishima et al. 2003). In a recent study, it was shown that apoA-I
promoter activity in HepG2 cells is inhibited by TNFα in a c-Jun-dependent manner
but no AP1-responsive element within the apoA-I promoter was reported to mediate
this effect (Parseghian et al. 2013). The inhibition of the expression of apoA-I and
other HDL genes in hepatocytes during inflammation could also be mediated by
HNF-4 which was previously shown to be negatively regulated by the TNFα/NF-κB
signaling pathway by physically interacting with NF-κB (Nikolaidou-
Neokosmidou et al. 2006).
1.3 Transcriptional Regulation of the ABCA1 Gene
The gene encoding the ATP-binding cassette transporter A1 (ABCA1) is expressed
in the liver, small intestine, macrophages, kidney, and various other tissues
(Langmann et al. 1999, 2003; Kielar et al. 2001; Wellington et al. 2002). ABCA1
is an important regulator of HDL biogenesis in the liver and facilitates the removal
of excess cholesterol from macrophages.
ABCA1 is particularly abundant in macrophages (Langmann et al. 1999).
ABCA1 expression in macrophages has little influence on HDL-C plasma levels
(Haghpassand et al. 2001) but is an important factor in the prevention of cholesterol
accumulation in the macrophages found in the atherosclerotic plaque and their
transformation into foam cells (Aiello et al. 2002). ABCA1 mRNA and protein are
very unstable, having a half-life of 1–2 h in murine macrophages (Wang and Oram
2002). Fine-tuning regulatory mechanisms (transcriptional regulation as well as
posttranscriptional and posttranslational modifications) are involved to ensure the
constant and inducible ABCA1 expression in macrophages. In this section, we will
focus on the transcriptional regulation of the ABCA1 gene with emphasis on
macrophages. Posttranscriptional and posttranslational regulation of this gene will
be discussed in later sections.
The human ABCA1 gene mapped to chromosome 9q31.1 is composed of
50 exons, which encode 2261-amino-acid residues (Santamarina-Fojo
et al. 2000). The ABCA1 gene promoter contains a TATA box localized 24 bp
upstream of the transcription initiation site, essential for promoter activity in
macrophages as well as in hepatocytes (Langmann et al. 2002). The engagement
of alternative promoters and transcription initiation sites localized upstream of the
first exon or inside the first intron of the gene enables the inducible and tissue-
specific expression regulation of ABCA1 gene (Huuskonen et al. 2003; Singaraja
et al. 2005). In addition, other transcriptional response elements of the promoter
influence the constitutive and tissue-specific expression of ABCA1 (Fig. 2).
1.3.1 Upregulatory Mechanisms of ABCA1 Gene Expression
The major transcription factors that upregulate ABCA1 gene expression in
macrophages are the nuclear receptors liver X receptors α and β (LXRα and
LXRβ), both expressed by this cell type. LXRs heterodimerize with the retinoic
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X receptor (RXRα) to bind to the direct repeats separated by four nucleotides
(direct repeat 4; DR4 elements) found at position62/47 of the ABCA1 promoter
(Costet et al. 2000). Additional but not well-characterized LXREs are present at the
intron 1 promoter of the ABCA1 gene (Singaraja et al. 2001). Since the LXRα
promoter is subject to autoregulation, the LXR-mediated gene expression is auto-
amplified (Laffitte et al. 2001a). The natural ligands of LXR are several
hydroxylated derivatives of cholesterol (oxysterols) and include
27-hydroxycholesterol (Schwartz et al. 2000; Fu et al. 2001), 22(R)-
hydroxycholesterol (Costet et al. 2000), 20(S)-hydroxycholesterol (Schwartz
et al. 2000), and desmosterol (Yang et al. 2006). Among these ligands,
27-hydroxycholesterol which is endogenously produced by the action of
CYP27A1 enzyme represents the sensor of cholesterol loading in macrophages.
In addition to these natural ligands, synthetic LXR ligands such as TO901317 have
also been developed. These synthetic LXR agonists upregulate ABCA1 in cultured
macrophages more efficiently than cholesterol loading via modified LDL particles
(Sparrow et al. 2002).
LXR tissue-selective gene transcription is dependent on co-regulatory proteins.
For example, data showed that the activation of the ABCA1 promoter by LXRα/
RXRα heterodimers and their ligands require Sp1 (Thymiakou et al. 2007). The
overexpression of Sp1 increased ABCA1 mRNA level in HeLa cells and enhanced
cellular cholesterol and phospholipid efflux in RAW 246.7 macrophages. Gel shift
experiments revealed in vitro binding of Sp1 to 85/91 and 151/156 GC
Fig. 2 Regulatory regions, transcription factors, and signaling molecules (cytokines, growth
factors, metabolites, drugs) that modulate the expression of the ABCA1 gene in macrophages
and other tissues. Arrows and block lines denote activation and repression, respectively. The
mechanisms are described in detail in the text. Abbreviations: retinoic acid receptor (RAR);
retinoid X receptor (RXR); liver X receptor (LXR); sterol regulatory element-binding protein
(SREBP); specificity protein 1 (Sp1); tumor necrosis factor α (TNFα), interleukin (IL); lipopoly-
saccharide (LPS); interferon γ (IFNγ); angiotensin II (AngII); nuclear factor kappa beta (NF-κB);
upstream stimulatory factor (USF); hypoxia-inducible factor (HIF); transforming growth factor β
(TGFβ); peroxisome proliferator-activated receptor (PPAR); Janus kinase (Jak); signal transducer
and activator of transcription (STAT)
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boxes. Moreover, it was shown that Sp3 competed with Sp1 for binding to the latter
GC box, acting as a repressor (Langmann et al. 2002). Physical interactions
between Sp1 and LXRα require the N-terminal region of LXRα, which includes
the DNA-binding domain and two different domains of Sp1: the transactivation
domain B and the DNA-binding domain (Thymiakou et al. 2007). LXR agonists,
such as the natural steroidal ligand 22(R)-hydroxycholesterol and the weak non-
steroidal ligand GSK418224, differentially recruit coactivators and corepressors
compared with full LXR agonists, such as the nonsteroidal ligand T0901317 (Albers
et al. 2006; Peng et al. 2008, 2011; Phelan et al. 2008). The synthetic oxysterol N,
N-dimethyl-3β-hydroxycholenamide (DMHCA) caused a differential induction of
the ABCA1 and the sterol regulatory element-binding protein (SREBP)-1c genes in
hepatic and macrophage cell lines, as well as in mice (Quinet et al. 2004). In
cholesterol-loaded or unloaded peritoneal macrophages, DMHCA increased
ABCA1 mRNA, whereas SREBP-1c mRNA levels were downregulated (Quinet
et al. 2004). Cineole, a small aromatic compound found in teas and herbs, consider-
ably stimulated the transactivation potential of LXRα and LXRβ and induced
ABCA1 expression in macrophages but significantly reduced the expression of
LXRα- and LXRα-responsive genes in hepatocytes (Jun et al. 2013). Another
LXR agonist, ATI-111, had a strong effect on ABCA1 expression in macrophages
as well as in the intestine and small effect on ABCA1 expression in the liver.
ATI-111 significantly stimulated SREBP-1c mRNA in some tissues but inhibited
the conversion of SREBP-1c precursor form into its active form (Peng et al. 2011).
These findings revealed that LXR agonists have a promising potential for the
upregulation of the ABCA1 transporter and the promotion of the cellular lipid
efflux capacity of macrophages. Due to the concomitant LXR-mediated
upregulation of two genes involved in the fatty acid biosynthesis, fatty acid
synthase (Joseph et al. 2002a), and SREBP-1c (Yoshikawa et al. 2001), the devel-
opment of LXR agonists for therapeutic uses has been limited by their adverse
effects that include hepatic steatosis and hypertriglyceridemia. In order to dissoci-
ate the positive effects of LXR agonists on cholesterol homeostasis from the
adverse effects on fatty acid metabolism, the next step will be the discovery of
new LXRβ-selective agonists and the synthesis of novel tissue-specific LXR
ligands with weaker transcriptional effects on SREBP-1c. SREBP-1a, a different
member of the SREBP family of proteins, binds to several sites present inside intron
1; however, the role of these elements in ABCA1 gene regulation is still unknown
(Thymiakou et al., unpublished observations) (Fig. 2).
Besides LXR, other nuclear receptors and transcription factors are involved in
ABCA1 gene regulation in macrophages. Retinoic acid receptor (RAR) activators
such as all-trans-retinoic acid and 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-
2-naphthalenyl)-1-propenyl]benzoic acid (arotinoid acid) were found to increase
ABCA1 mRNA and protein levels in macrophages (Costet et al. 2003).
Co-transfection experiments showed that the same DR4 promoter element of the
ABCA1 promoter binds RXR heterodimers in the following order: RARγ/RXRα
bound stronger and activated the human ABCA1 promoter, and RARα/RXRα
bound weaker, while no RARβ/RXRα binding was detected. However, in
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macrophages from RARγ/ mice, arotinoid acid still induced ABCA1 gene
expression and caused marked upregulation of RARα, suggesting that high levels
of RARα can compensate for the absence of RARγ (Costet et al. 2003).
Peroxisome proliferator-activated receptors α (PPARα) and γ (PPARγ) are both
expressed in human macrophages where they exert anti-inflammatory effects. The
hydroxylated derivative of linoleic acid, 13-hydroxy linoleic acid, a natural PPAR
agonist, and pioglitazone (PPARγ agonist) increased PPAR transcriptional activity
and induced ABCA1 gene expression in macrophages (Kammerer et al. 2011;
Ozasa et al. 2011). However, data suggest that these effects are indirect and most
probably are mediated by LXRα (Chinetti et al. 2001). PPARδ activators appeared
to induce ABCA1 gene expression and cholesterol efflux moderately and to
increase HDL levels in an obese-monkey model (Oliver et al. 2001).
Recent data showed that Clock, a key transcription factor that controls circadian
rhythm, is involved in ABCA1 regulation in macrophages (Pan et al. 2013). The
dominant-negative Clock mutant protein (ClockΔ19/Δ19) enhanced plasma
cholesterol and atherosclerosis. Mutant ClockΔ19/19/apoE/ mice had macro-
phage dysfunction, expressed low levels of ABCA1, and had higher levels of
scavenger receptors. Molecular studies revealed that Clock regulated ABCA1
expression in macrophages by modulating the activity of upstream stimulatory
factor 2 (Pan et al. 2013).
Experimental data showed that signaling molecules upregulate ABCA1 expres-
sion in macrophages, but the fine-tuning mechanism of modulation and the regu-
latory regions involved remain to be elucidated. Transforming growth factor β1
(TGFβ1) increased ABCA1 mRNA levels in cholesterol-loaded macrophages
(Argmann et al. 2001; Panousis et al. 2001). It was demonstrated that in THP-1
macrophage-derived foam cells, the LXRα pathway is involved in TGFβ-mediated
upregulation of ABCA1 expression (Hu et al. 2010b). Interleukin-6 (IL-6) signifi-
cantly increased ABCA1 at both the mRNA and protein levels. This effect was
abolished by selective inhibition of the JAK2/STAT3 signaling pathway (Frisdal
et al. 2011). ABCA1 mRNA levels were significantly increased by estradiol
treatment of macrophages for a short period of time, suggesting a direct activation
of the ABCA1 promoter via the estrogen receptor β (Schmitz and Langmann 2005).
Membrane-permeable analogues of cyclic adenosine monophosphate (cAMP)
induced the ABCA1 mRNA in macrophages and other cells by an unknown
mechanism (Lin and Bornfeldt 2002). Inhibitors that are able to block the action
of phosphodiesterase 4 on cAMP have been found to increase ABCA1 mRNA and
cellular cholesterol efflux (Lin and Bornfeldt 2002). Verapamil, a calcium channel
blocker, enhanced ABCA1 transcription by an LXR-independent process (Suzuki
et al. 2004). Toll-like receptor 2 agonist Pam(3)CSK(4) upregulated ABCA1 gene
expression in RAW 264.7 macrophages via the activation of the PKCη/phospho-
lipase D2 signaling pathway (Park et al. 2013). S-Allylcysteine, the most abundant
organosulfur compound in aged garlic extract, also elevated ABCA1 content in
human THP-1 macrophages (Malekpour-Dehkordi et al. 2013). The data showed
that stimulation with CXCL5 that has a protective role in atherosclerosis (Rousselle
128 D. Kardassis et al.
et al. 2013) induced ABCA1 expression in alternatively activated
(M2) macrophages but not in classically activated (M1) macrophages.
1.3.2 Negative Regulation of ABCA1 Gene Transcription
The thyroid hormone T3 strongly suppressed ABCA1 gene transcription
(Huuskonen et al. 2004). It was demonstrated that T3 significantly inhibited the
ability of oxysterols to activate LXR. Moreover, the TR/RXR heterodimers
competed with LXR/RXR for the DR4 element in the ABCA1 promoter
(Huuskonen et al. 2004). A reciprocal negative cross talk exists between LXRs
and STAT1 based on the competition for CREB-binding protein (Pascual-Garcia
et al. 2013). This may explain the IFNγ-mediated downregulation of ABCA1 in
cholesterol-loaded macrophages (Panousis and Zuckerman 2000; Argmann
et al. 2001; Ma et al. 2013). Moreover, TNFα downregulates ABCA1 as well as
LXRα expression in macrophages via a PKCθ-dependent pathway (Ma et al. 2013).
Unsaturated fatty acids decrease the expression of ABCA1 in RAW 264.7
macrophages by a mechanism that involves LXR/RXR binding to the promoter
(Uehara et al. 2007) and by modulation of the histone acetylation state
(Ku et al. 2012). In MCSF-activated human monocytes, linoleic acid decreases
ABCA1 gene expression (Mauerer et al. 2009). Geranylgeranyl pyrophosphate, a
product of the mevalonate pathway that is used for protein isoprenylation,
suppresses LXR-induced ABCA1 synthesis in two ways: as an antagonist of the
LXR interaction with the steroid receptor coactivator-1 (SRC-1) and as an activator
of Rho GTP-binding proteins (Gan et al. 2001).
Among the transcription factors that downregulate ABCA1 expression in
macrophages in an LXR-independent manner is the SCAN domain-containing
zinc finger transcription factor ZNF202 which binds to a GnT motif in the region
234/215 of the ABCA1 promoter (Porsch-Ozcurumez et al. 2001). High intra-
cellular levels of ZNF202 prevented LXR/RXR-mediated induction of the ABCA1
promoter in response to oxysterols (Porsch-Ozcurumez et al. 2001).
The conserved E-box at position 140 binds transcription factors that modulate
the ABCA1 gene expression. Experimental data indicated that upstream stimu-
latory factors (USF) 1 and 2, hepatocyte nuclear factor-1α (HNF-1α), and
fos-related antigen (Fra)2 bind to the intact E-box of the human ABCA1 promoter
and differentially modulate the gene expression: USF1 and USF2 enhanced and
Fra2 repressed ABCA1 promoter activity (Langmann et al. 2002; Yang et al. 2002).
The same E-box element also binds the sterol regulatory element-binding protein
2 (SREBP-2), a key regulator of cholesterol metabolism, which suppresses ABCA1
gene transcription in response to cholesterol depletion (73).
ABCA1 gene expression was severely decreased in the liver and peritoneal
macrophages of diabetic mice (Uehara et al. 2002). This observation was explained
using in vitro models in which it was revealed that acetoacetate downregulates
ABCA1 mRNA and protein in HepG2 hepatocytes and RAW 264.7 macrophages
(Uehara et al. 2002) and thus high glucose concentration decreases ABCA1 gene
expression in MCSF-activated monocytes (Mauerer et al. 2009). Data showed that
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the treatment of THP-1 macrophages with 100 nM dexamethasone, a potent
synthetic ligand of the glucocorticoid receptor, decreases the expression of the
ABCA1 gene (Sporstol et al. 2007).
LPS downregulates ABCA1 in macrophages; this inhibition was reverted by the
treatment with betulinic acid acting via the downregulation of miR-33 and suppres-
sion of NF-κB pathway (Zhao et al. 2013). IL-18 and IL-12 synergistically decrease
ABCA1 levels in THP-1 macrophage-derived foam cells through the IL-18 recep-
tor/NF-κB/ZNF202 signaling pathway (Yu et al. 2012). ABCA1 expression was
strongly suppressed by angiotensin (Ang) II at both mRNA and protein levels in a
dose-dependent manner in THP-1-derived macrophages, whereas ABCG1 expres-
sion was not affected. The effect of Ang II on ABCA1 expression could be
mediated by the angiotensin II type 1 (AT1) receptor (Chen et al. 2012a). It was
demonstrated that clinically relevant concentrations of homocysteine (Hcy)
decreased the mRNA and protein expression levels of ABCA1 in macrophages. It
was revealed that mRNA expression and the activity of DNA methyltransferase
were increased by Hcy, which may explain the higher DNA methylation level of
ABCA1 gene in macrophages incubated with Hcy (Liang et al. 2013).
1.4 Transcriptional Regulation of the ABCG1 Gene
ABCG1 mediates cholesterol removal from macrophages to HDL particles, but not
to lipid-free apoA-I (Kennedy et al. 2005; Fitzgerald et al. 2010). Although recent
data showed that the combined macrophage deficiency of ABCA1/G1 is
pro-atherogenic, probably by promoting plaque inflammation (Westerterp
et al. 2013), the data concerning the role of ABCG1 expression in macrophages is
controversial. Two independent groups reported that LDLR/ mice lacking
macrophage ABCG1 show decreased atherosclerotic lesions (Baldan et al. 2006;
Ranalletta et al. 2006), while others reported that the absence of macrophage
ABCG1 causes a modest increase in atherosclerotic lesions (Out et al. 2006).
These contradictory results may be explained by recent data showing that the
absence of ABCG1 leads to increased lesions in early stages of atherosclerosis
but causes retarded lesion progression in more advanced stages of atherosclerosis in
LDLR/ mice, suggesting that the influence of ABCG1 deficiency on lesion
development depends on the stage of atherogenesis (Meurs et al. 2012).
The human ABCG1 gene has been mapped to chromosome 21q22.3 and encodes
for a 678-amino-acid protein of 75.5 kDa molecular mass (Chen et al. 1996). The
ABCG1 gene spans more than 70 kb and includes 15 exons, each containing
between 30 and 1,081 bp, while the intron size is between 137 bp and more than
45 kb. All exon-intron boundaries display the canonical GT/AG sequences.
In contrast to the ABCA1 gene, the ABCG1 gene does not contain a canonical
TATA box in the promoter (Langmann et al. 2000).
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The regulation of ABCG1 expression has similarities with that of ABCA1
(Fig. 3). Thus, LXR plays an important role in ABCG1 promoter activation.
Experimental data indicated that various LXR ligands upregulate ABCG1 expres-
sion. ATI-111, a novel steroidal LXR agonist, induces ABCG1 mRNA expression
in peritoneal macrophages more potently than T0901317 and inhibits its expression
in the liver, suggesting tissue selectivity (Peng et al. 2011). Different natural
compounds, such as cineole and fucosterol that are LXR activators, are able to
increase ABCG1 levels in macrophages (Hoang et al. 2012; Jun et al. 2013). Recent
data showed that the knockdown of LXRα impaired cholesterol efflux in human
primary macrophages, while LXRβ silencing had no detectable impact on the
expression of LXR target genes such as ABCA1 and ABCG1 and did not affect
cholesterol efflux (Ishibashi et al. 2013). The indirect effects of LXR in ABCG1
regulation were recently shown. Adiponectin treatment significantly increased
ABCG1 mRNA and protein levels in macrophages from diabetic patients, whereas
the pharmacological or genetic inhibition of LXR abrogated this enhancement;
these data demonstrated that the mechanism of adiponectin-mediated upregulation
of ABCG1 includes LXRα (Wang et al. 2013b). Similar with ABCA1, TGFβ
upregulates the expression of ABCG1, while unsaturated fatty acids suppress
ABCG1 expression via the LXR pathway (Uehara et al. 2007; Hu et al. 2010b).
The analysis of potential regulatory elements in the promoter region carried out
using the MatInspector program identified multiple Sp1 sites at positions 184,
382, and 566, an AP2 binding site at position 222, a NF-κB site at position
338, an E-box motif at position 233, a sterol regulatory element at position
660, and the NFY binding site at position 198 in ABCG1 proximal promoter
(Langmann et al. 2000). A functional genetic variant of the ABCG1 promoter
associated with an increased risk of myocardial infarction and ischemic heart
disease in the general population was revealed (Schou et al. 2012). This study
Fig. 3 Regulatory regions, transcription factors, and signaling molecules (cytokines, growth
factors, metabolites, drugs) that modulate the expression of the ABCG1 gene. Arrows and block
lines denote activation and repression, respectively. The mechanisms are described in detail in the
text. Abbreviations: conjugated linoleic acid (CLA); glycogen synthase kinase 3β (GSK3β); sterol
regulatory element-binding protein (SREBP); specificity protein 1 (Sp1)
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showed that the ABCG1 expression was decreased by approximately 40 % in
g.-376C>T heterozygotes versus noncarriers. This gene polymorphism is included
in a Sp1 binding site located at position382/373 in the ABCG1 promoter. Thus,
the presence of the 376 T allele reduced the binding and transactivation of the
promoter by Sp1, leading to a decreased ABCG1 expression (Schou et al. 2012).
ZNF202 was identified as a transcriptional repressor of ABCG1 gene which
binds at position 560 in the ABCG1 promoter (Porsch-Ozcurumez et al. 2001).
Recently, microbiotic and dietary factors were shown to regulate the ABCG1
expression. Protocatechuic acid (PCA), a gut microbiota metabolite of cyanidin-3
formed by 0-β-glucoside, exerts an anti-atherogenic effect partially through the
inhibition of miR-10b-mediated downregulation of ABCG1 expression (Wang
et al. 2012a). Extra-virgin olive oil intake has been shown to improve the capacity
of HDL to mediate cholesterol efflux and increased ABCG1 and ABCA1 expres-
sion in human macrophages (Helal et al. 2013). Conjugated linoleic acids (CLAs)
are minor components of the diet with many reported biological activities. It was
revealed that in MCSF-differentiated monocytes, trans-9,trans-11-CLA, but not
cis-9,trans-11-CLA and trans-10,cis-12-CLA, activated ABCG1 via SREBP-1c
(Ecker et al. 2007). In addition, it was demonstrated that palmitic acid upregulates
the ABCG1 gene, while high glucose concentration decreased ABCG1 gene
expression in MCSF-activated human monocytes (Mauerer et al. 2009).
Among the downregulators of ABCG1, low doses of LPS strongly reduce the
expression of ABCG1 in bone marrow-derived macrophages through IL-1 receptor-
associated kinase 1 (IRAK-1)/glycogen synthase kinase 3β (GSK3β)/retinoic acid
receptor α (RARα) signaling pathway (Maitra and Li 2013). HMG-CoA reductase
inhibitors, simvastatin and atorvastatin, decreased ABCG1-mediated cholesterol
efflux in human macrophages, despite the fact that the protein expression remained
unaltered (Wang et al. 2013c). In THP-1 monocytes, 100 nM dexamethasone, a
synthetic glucocorticoid, inhibited the mRNA expression of ABCG1, although the
glucocorticoid receptor expression was very low in this cell line (Sporstol
et al. 2007). IL-22, a member of the IL-10 cytokine family secreted primarily by
Th17 and Th22 subsets of T lymphocytes, was induced by S100/calgranulin and
impaired cholesterol efflux in macrophages by downregulation of ABCG1 (Chellan
et al. 2013).
1.5 Transcriptional Regulation of the Apolipoprotein E Gene
Apolipoprotein E (apoE), a glycoprotein of 35 kDa, plays an important role in
plasma cholesterol level regulation and in cholesterol efflux, as documented by
studies in patients and animal models with apoE deficiency or mutated apoE genes
(Nakashima et al. 1994; Linton et al. 1995; von Eckardstein 1996; Van Eck
et al. 1997; Grainger et al. 2004; Ali et al. 2005; Davignon 2005; Raffai
et al. 2005). ApoE is mainly synthesized by the liver but also by various cells and
peripheral tissues (Zannis et al. 2001b). ApoE is a marker for the developmental
state of macrophages; the culture of mouse bone marrow cells in vitro showed that
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mature macrophages, but not their monocytic precursors, synthesized apoE (Werb
and Chin 1983c). At the site of atherosclerotic lesion, apoE is provided by
infiltrated macrophages. Transgenic mice expressing apoE only in macrophages
are protected against atherosclerosis, even though the plasma levels of apoE are
exceedingly low and the animals are hypercholesterolemic (Bellosta et al. 1995). In
contrast, transgenic mice with normal levels of apoE in plasma, but not in
macrophages, are more susceptible to atherosclerosis (Fazio et al. 1997). ApoE
secreted by macrophages within the atherosclerotic plaque facilitates the choles-
terol efflux to exogenous acceptors (such as HDL), thus assisting the reverse
cholesterol transport to the liver. The uptake of acetylated LDL or cholesterol
ester-rich β-VLDL into peritoneal macrophages stimulates apoE synthesis and
secretion (Basu et al. 1981).
The human apoE gene is located on chromosome 19 at the 50 end of a cluster
containing also apoC-I, apoC-IV, and apoC-II genes (Myklebost and Rogne 1988;
Smit et al. 1988; Allan et al. 1995a, b). The regulation of apolipoprotein E gene
transcription is a highly complex process and requires the interaction of transcrip-
tion factors with the proximal promoters but also with the distal regulatory regions
(Fig. 4).
Fig. 4 Regulatory regions, transcription factors, and signaling molecules (cytokines, growth
factors, metabolites, drugs) that modulate the expression of the apoE gene. Arrows and block
lines denote activation and repression, respectively. The mechanisms are described in detail in the
text. Abbreviations: glucocorticoid receptor (GR); signal transducer and activator of transcription
(STAT); Jun N-terminal kinase (JNK); retinoid X receptor (RXR); liver X receptor (LXR);
specificity protein 1 (Sp1); activator protein 2 (AP2); nuclear factor kappa beta (NF-κB); upstream
regulatory region 3 binding protein (URE3BP); lipopolysaccharide (LPS); multienhancer
2 (ME.2); transforming growth factor β (TGFβ)
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1.5.1 Proximal Regulatory Binding Sites Involved in the apoE Gene
Expression
The proximal apoE promoter is well conserved in humans and mice, having the
same localization of TATA box and GC box (Rajavashisth et al. 1985; Horiuchi
et al. 1989). Multiple positive and negative elements that modulate apoE gene
expression have been detected on the apoE promoter, using different in vitro
systems (Larkin et al. 2000; Zannis et al. 2001b). Smith et al. analyzed the apoE
promoter in both expressing (HepG2) and non-expressing (HeLa) cells (Smith
et al. 1988). Within the proximal 50-flanking sequence and the first intron, eight
regions were identified which had a positive effect and three regions with a negative
effect on apoE expression, in both HepG2 and HeLa cells (Smith et al. 1988). The
proximal apoE promoter contains a GC box transcriptional control element at 59/
45, a nonspecific enhancer element at 366/246, an upstream regulatory ele-
ment (URE1) at 193/124, and a downstream regulatory element at +44/+262
(Paik et al. 1988). Within URE1, a sequence spanning 161/141, defined as a
positive element for transcription, has the ability to act alone as an enhancer
element (Chang et al. 1990). This element interacts with Sp1 transcription factor
that constitutively binds the GC box motif, suggesting that Sp1 may play an
important role in the basal level of apoE expression, as well as in the activity of
this enhancer element. Another regulatory element, termed URE3, was identified at
position 101/89 and found to bind a 300 kDa protein from placental nuclear
extracts termed URE3 BP (Jo et al. 1995). DNase I footprinting revealed the
existence of two binding sites for recombinant AP2 in the regions from 48/74
and from 107/135 of the apoE promoter (Olaisen et al. 1982; Smith et al. 1988;
Garcia et al. 1996; Salero et al. 2001, 2003). Gel mobility-shift assays showed the
direct binding of LXRα/RXRα and LXRβ/RXRα to a low-affinity LXRE present in
the region 494/465 of the proximal promoter (Laffitte et al. 2001b). Other
studies revealed that USF binds to an atypical E-box located in the 101/91
region of the apoE promoter (Salero et al. 2003). The same group found that Zic1
and Zic2 transcription factors can bind to three binding sites located at 65/54,
136/125, and 185/174 in the apoE promoter and stimulate apoE gene
expression (Salero et al. 2001).
Bacterial endotoxin and other inflammatory agents decrease apoE production
(Werb and Chin 1983a, b; Gafencu et al. 2007). The apoE downregulation in
macrophages impaired the local beneficial effect of apoE during the plaque devel-
opment. As a result, despite the fact that macrophages are present in the lesion, their
ability to regress atherosclerosis is seriously compromised. We have previously
reported the mechanisms of apoE downregulation in macrophages exposed to
inflammatory conditions, similar to those found at the atherosclerotic site (Gafencu
et al. 2007). Tumor progression locus 2 (Tpl2) and mitogen-activated protein
kinase/ERK kinase kinase 1 (MEKK1) were identified as the kinases that are
primarily responsible for the downregulation of apoE promoter activity by LPS.
Tpl2 and MEKK1 signaling pathways converge to NF-κB and AP1, acting on the
apoE core promoter 55/+73 (Gafencu et al. 2007).
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1.5.2 Distal Regulatory Binding Sites That Modulate apoE Gene
Expression in Macrophages
Despite this complex transcription factor machinery that may be targeted to the
apoE promoter, the promoter itself lacks the ability to direct gene transcription
in vivo in any cells, in the absence of the distal enhancers (Shih et al. 2000). In
many tissues, cell-specific distal enhancers regulate the expression of genes in the
apoE/apoC-I/apoC-I0/apoC-IV/apoC-II gene cluster (Shih et al. 2000). The expres-
sion of apoE in macrophages is controlled by two homologous enhancers (95 %
identical in sequence), designated as multienhancer 1 (ME.1) and multienhancer
2 (ME.2), containing 620 and 619 nucleotides, respectively (Shih et al. 2000).
These enhancers are located at 3.3 and 15.9 kb downstream of the apoE gene,
respectively. We demonstrated by chromosome conformational capture (3C) and
transient transfections that both ME.1 and ME.2 can interact with the apoE pro-
moter only in phorbol 12-myristate 13-acetate (PMA)-differentiated macrophages,
but not in undifferentiated monocytes (Trusca et al. 2011). The results showed that
the interactions take place in antisense orientation of the promoter and ME.1/2. Our
data obtained using a series of deletion mutants of the promoter or of the ME.2
identified the fragment 100/+73 as the minimal region of the apoE promoter that
is activated by the ME.2. We showed that the entire sequence of ME.2 is necessary
for an optimal interaction with the apoE promoter, but the 50 region of ME.2 is more
important than 30 region for enhancing apoE promoter activity (Trusca et al. 2011).
The interaction of the apoE promoter with ME.1/2 facilitates the transcriptional
enhancement of the apoE gene by various transcription factors.
LXRα and LXRβ and their oxysterol ligands are key regulators of apoE expres-
sion in macrophages (Laffitte et al. 2001b; Joseph et al. 2002b; Mak et al. 2002b).
The ability of oxysterols and synthetic ligands to regulate apoE expression in
peritoneal macrophages as well as in adipose tissue is reduced in LXRα/ or
LXRβ/ mice and abolished in double knockouts. However, basal expression of
apoE is not compromised in LXR null mice, suggesting that LXRs mediate lipid-
inducible expression rather than tissue-specific expression of this gene (Laffitte
et al. 2001b). Data revealed that LXR/RXR binds to a low-affinity LXRE present in
the apoE promoter as well as a high-affinity site conserved in both human ME.1 and
ME.2 (Laffitte et al. 2001b). Experimental data revealed that the ligand activation
of the LXR/RXR heterodimer enhanced the activity of the reporter constructs under
the control of human ME.1 or ME.2 fused to the apoE proximal promoter (Laffitte
et al. 2001b). Oxysterol-binding protein-related protein 1S (ORP1S) translocates
from the cytoplasm to the nucleus in response to sterol binding and then binds to
LXRs, promoting the binding of LXRs to LXREs. Thus, ORP1S mediates the
LXR-dependent transcription via the ME.1 and ME.2 of the apoE gene (Lee
et al. 2012). An interesting finding was that the induction of apoE gene expression
by LXR agonists is attenuated by inhibitors of JNK and PI3K pathways (Huwait
et al. 2011). A similar inhibition was noticed in the case of TGFβ-induced expres-
sion of apoE, which was prevented by pharmacological inhibitors of JNK, p38
kinase, and casein kinase 2 (Singh and Ramji 2006).
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The synthetic glucocorticoid receptor (GR) ligand, dexamethasone, increased
apoE mRNA levels in mature macrophages up to sixfold over basal levels
(Zuckerman et al. 1993). In silico analysis of the ME.1 and ME.2 revealed some
transcription factor binding motifs for the GR (Shih et al. 2000). The presence of
these GR binding sites in the multienhancers may explain the apoE upregulation by
GR ligands, but the biological activity of these GR biding sites remains to be
revealed.
TRANSFAC analysis of the apoE promoter, ME.1, and ME.2 showed that
STAT1 transcription factor has a binding site only on the ME.2. Our data showed
that this binding site is biologically active and STAT1 specifically upregulates apoE
gene expression via ME.2, in macrophages, but not in hepatocytes. The STAT1
binding site was located in the 174/182 region of ME.2 (Trusca et al. 2011).
Interestingly, a simultaneous increase in the expression of apoE and STAT1 was
recorded after monocyte differentiation with PMA treatment (for 4 h). Our model
proposed that after DNA bending, which probably takes place during monocyte
differentiation, STAT1 bound on ME.2 interacts with the transcription initiation
complex, leading to the activation of apoE expression. In addition, STAT1 can
interact and cooperate with other transcription factors bound on the ME.2 or on the
apoE promoter, for the modulation of apoE gene expression. Recently, we have
revealed that STAT1 can interact with RXR and modulate gene expression of the
apoC-II gene (Trusca et al. 2012). Since RXRα binds to the ME.2, we can speculate
that apoE expression in macrophages may be modulated by the STAT1-RXRα
interactions, similarly with apoC-II.
1.6 Transcriptional Regulation of the Human apoM Gene
in the Liver
Apolipoprotein M (apoM) belongs to the lipocalin protein superfamily and differs
from typical water-soluble apolipoproteins by its tertiary structure (Dahlback and
Nielsen 2009; Nielsen et al. 2009). ApoM is secreted primarily by the liver and
associates with HDL particles through its retained N-terminal signal peptide (Axler
et al. 2008; Christoffersen et al. 2008). The silencing of the endogenous apoM gene
in mice showed a loss of pre-β-HDL particles and formation of large HDL particles
(Wolfrum et al. 2005). In addition to its role in HDL remodeling, it was shown that
apoM is the sole carrier of the bioactive lipid sphingosine 1 phosphate (S1P) in
HDL, thus mediating many of the atheroprotective properties of HDL in the
endothelium (Christoffersen et al. 2011; Arkensteijn et al. 2013; Christoffersen
and Nielsen 2013).
The expression of apoM in the liver is primarily controlled by hepatocyte
nuclear factor-1α (HNF-1α) (Richter et al. 2003). HNF-1α/ mice are
characterized by the complete absence of apoM from plasma. The plasma
concentrations of other apolipoproteins in HNF-1α/ mice were either similar
(apoA-II, apoB, apoC) or increased (apoA-I, apoE) compared to wild-type mice.
This was not due to the absence of apoM since restoration of apoM gene expression
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in the liver via adenovirus-mediated gene transfer could not rescue the abnormal
apolipoprotein profile (Wolfrum et al. 2005). The analysis of the plasma lipoprotein
profile of HNF-1α/ mice showed that similar to the apoM gene-silenced mice,
plasma cholesterol was primarily associated with the HDL fraction. In addition, an
abnormal large apoE-enriched HDL fraction that was identified as HDLc or HDL1
was observed, suggesting that this abnormal lipid profile in HNF-1α/ mice may
be caused by the lack of apoM (Shih et al. 2001). In humans, HNF-1α regulates
apoM gene expression through direct binding to a conserved DNA element located
in the proximal apoM promoter region between nucleotides 55 and 41 (Richter
et al. 2003).
ApoM gene expression in the liver is negatively regulated during inflammation
or infection via pro-inflammatory cytokines such as TNFα or IL-1β (Feingold
et al. 2008). The HNF-1α binding element in the proximal human apoM promoter
is a dual-specificity regulatory element that mediates the activation or repression of
apoM promoter activity by HNF-1 and by activator protein 1 (AP1) proteins (c-Jun
and JunB), respectively, in hepatic cells (Mosialou et al. 2011). Competition
experiments showed that the binding of Jun proteins and HNF-1α to the apoM
promoter is mutually exclusive and chromatin immunoprecipitation assays
established that AP1 activation leads to the recruitment of c-Jun and JunB proteins
to the proximal apoM promoter with the simultaneous displacement of HNF-1
(Mosialou et al. 2011). A similar mechanism of transcriptional repression via
dual-specificity AP1-/HNF-1-responsive elements has been demonstrated in the
case of the promoter of the human apolipoprotein A-II gene (Mosialou et al. 2011).
AP1 factors were shown to inhibit the promoters of the apolipoprotein C-III
(Hadzopoulou-Cladaras et al. 1998) and ABCA1 (Mosialou and Kardassis unpub-
lished) genes in hepatic cells suggesting a broader role of AP1 factors in lipoprotein
metabolism in the liver during inflammation.
Besides HNF-1α, apoM gene transcription in the liver has been shown to be
controlled positively by liver receptor homologue-1 (LRH-1) and forkhead box A2
(FOXA2) transcription factors which bind to distinct sites on the proximal apoM
promoter (Venteclef et al. 2008; Wolfrum et al. 2008). Bile acids suppress apoM
expression in vivo by inhibiting LRH-1 transcriptional activity via the recruitment
of small heterodimer partner (SHP) to the apoM promoter (Venteclef et al. 2008).
Insulin, insulin-like growth factor I (IGF-I), and IGF-I potential peptide
(IGF-IPP) were all shown to inhibit apoM gene expression in a dose- and time-
dependent manner in primary human and murine hepatocytes via a signal transduc-
tion pathway that involves the serial activation of phosphatidylinositol 3-kinase
(PI3K) and protein kinase B (PKB) and the inactivation of Foxa2 (Xu et al. 2006).
In HepG2 cells, glucose and insulin inhibited apoM gene expression in an additive
manner, while in hyperglycemic rats, serum apoM concentrations and hepatic
apoM mRNA levels were significantly reduced (Zhang et al. 2007).
The human apoM gene is under the control of various orphan- and ligand-
dependent nuclear receptors (Mosialou et al. 2010). The overexpression via adeno-
virus and silencing via siRNA established that HNF-4 is an important regulator of
apoM gene transcription in hepatic cells (Mosialou et al. 2010). In addition to
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HNF-4, homodimers of retinoid X receptor and heterodimers of retinoid X receptor
with receptors for retinoic acid, thyroid hormone, fibrates (peroxisome proliferator-
activated receptor), and oxysterols (liver X receptor) were shown to bind with
different affinities to the proximal HRE in vitro and in vivo (Mosialou
et al. 2010). These findings provide novel insights into the role of apoM in the
regulation of HDL by steroid hormones and into the development of novel
HDL-based therapies for diseases such as diabetes, obesity, metabolic syndrome,
and coronary artery disease that affect a large proportion of the population in
Western countries.
1.7 Transcriptional Regulation of the CETP Gene
The gene encoding the cholesterol ester transfer protein (CETP) plays an important
role in human HDL metabolism because it facilitates the transfer of cholesteryl
esters from mature spherical HDL particles to VLDL/IDL lipoproteins in exchange
of triglycerides and its activity determines the plasma levels of HDL cholesterol
(von Eckardstein et al. 2005; Tall et al. 2008).
The CETP gene is expressed mainly in the liver, adipose tissue, and spleen and at
lower levels in the small intestine, adrenal, kidneys, and heart (Jiang et al. 1991;
Radeau et al. 1995). Atherogenic diets were shown to increase CETP mRNA levels
in rabbits and in human CETP transgenic mice (Quinet et al. 1990; Jiang
et al. 1992). Both LXRs and SREBPs were shown to bind to regulatory elements
on the promoter of the CETP gene and regulate its transcription in response to
intracellular cholesterol levels (Gauthier et al. 1999; Luo and Tall 2000). It was
shown recently that synthetic LXR agonists enhanced plasma CETP activity and
decreased HDL-C levels in cynomolgus monkeys and human CETP transgenic
mice (Honzumi et al. 2010). The induction of CETP gene expression by the LXR
agonist was significantly reduced by knocking down the expression of LXRα but
not LXRβ both ex vivo and in mice (Honzumi et al. 2010). In another study, it was
shown that the LXR agonist T0901317 markedly increased CETP mRNA levels
and CETP production in human differentiated macrophages but not in human
peripheral blood monocytes (Lakomy et al. 2009). In inflammatory mouse and
human macrophages, LXR-mediated CETP gene upregulation was inhibited and
this inhibition was independent of lipid loading. It was concluded that
LXR-mediated induction of human CETP expression is switched on during
monocyte-to-macrophage differentiation and is abrogated in inflammatory
macrophages (Lakomy et al. 2009).
Other factors that regulate CETP promoter activity include Yin Yang 1 (YY1)
that binds to the same element as SREBPs (Gauthier et al. 1999), the LRH-1 that
potentiates the sterol-mediated induction of the CETP gene by LXRs (Luo
et al. 2001), the orphan nuclear receptor ARP-1 (Gaudet and Ginsburg 1995) that
inhibits CETP promoter activity, the retinoic acid receptor (RAR) which regulates
CETP gene expression in response to all-trans-retinoic acid (Jeoung et al. 1999),
and the CCAAT/enhancer-binding protein (C/EBP) which is an activator of CETP
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gene expression (Agellon et al. 1992). Binding sites for the ubiquitous transcription
factors SP1 and SP3 have been identified on the CETP promoter at positions 690,
623, and 37 and seem to be essential for the basal CETP promoter activity
(Le Goff et al. 2003).
CETP gene expression was shown recently to be under regulation by bile acids
and their nuclear receptor farnesoid X receptor (FXR) (Gautier et al. 2013). It was
shown that plasma CETP activity and mass was higher in patients with cholestasis
than controls and this was associated with lower HDL-C levels (Gautier et al. 2013).
In agreement with this observation, bile acid feeding of APOE3*Leiden mice
expressing the human CETP transgene controlled by its endogenous promoter
decreased HDL-C and increased plasma CETP activity and mass. An FXR response
element (FXRE) was identified in the first intron of the human CETP gene which
could be responsible for the upregulation of CETP gene expression in response to
bile acids (Gautier et al. 2013). In another study, it was shown that FXRα binds to
DR4 LXRE that is present in the proximal CETP promoter and represses
LXR-mediated transactivation of the CETP promoter by a competition mechanism
(Park et al. 2008).
1.8 Transcriptional Regulation of the PLTP Gene
Phospholipid transfer protein (PLTP) belongs to the lipopolysaccharide (LPS)
binding/lipid transfer gene family that includes the LPS-binding protein (LBP),
the neutrophil bactericidal/permeability-increasing protein (BPI), and the
cholesteryl ester transfer protein (CETP). PLTP is essential in the transfer of very
low-density lipoprotein phospholipids into HDL (Jiang et al. 2012).
PLTP is expressed ubiquitously, but the highest expression levels in human
tissues were observed in the ovary, thymus, placenta, and lung (Day et al. 1994).
Taking into account the organ size involved, the liver and small intestine appear to
be important sites for the overall PLTP expression. A high-fat, high-cholesterol diet
causes a significant increase in PLTP activity and in mRNA levels. Plasma PLTP
activity and PLTP mRNA levels in the liver and adipose tissues were significantly
decreased following LPS administration (Jiang and Bruce 1995).
An FXR-responsive element (FXRE) has been found in the proximal PLTP
promoter that binds FXRα/RXRα heterodimers and mediates the response of the
PLTP promoter to bile acids (Urizar et al. 2000). Fibrates were shown to increase
PLTP gene expression by activating PPARs which bind to three PPAR-responsive
elements on the PLTP promoter (Tu and Albers 1999; Bouly et al. 2001). Two of
these PPAR-responsive elements also seem to be responsible for the induction of
PLTP expression by high glucose (Tu and Albers 2001).
The human PLTP promoter contains at least two LXR-responsive elements, one
in the proximal and one in the distal region, that were shown to mediate PLTP gene
regulation by oxysterols ex vivo and in vivo (Cao et al. 2002; Mak et al. 2002a;
Laffitte et al. 2003). It was recently demonstrated that LXR agonists activate
triglyceride synthesis and PLTP gene transcription by activating SREBP-1c
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(Okazaki et al. 2010). In concert with the increase in triglyceride synthesis, the
increased PLTP caused triglyceride incorporation into abnormally large VLDL
particles which were removed from plasma by LDL receptors, whereas in the
absence of LDL receptors, the large VLDLs accumulated and caused massive
hypertriglyceridemia (Okazaki et al. 2010).
Recently, microarray analysis following alteration of p53 status in several
human- and mouse-derived cells identified a group of 341 genes whose expression
was induced by p53 in the liver-derived cell line HepG2 (Goldstein et al. 2012).
Twenty of these genes encode proteins involved in many aspects of lipid homeo-
stasis including PLTP (Goldstein et al. 2012).
1.9 Transcriptional Regulation of the Bile Acid Transporters
ABCG5/ABCG8
ATP-binding cassette half-transporters G5 and G8 (ABCG5 and ABCG8) play
important roles in the control of sterol excretion from the liver (Fitzgerald
et al. 2010; Tarling and Edwards 2012; Li et al. 2013; Yu et al. 2014). Mutations
in either of these transporters leads to β-sitosterolemia, an autosomal recessive
disease characterized by premature coronary atherosclerosis and elevated levels of
phytosterols in plasma (Fitzgerald et al. 2010; Tarling and Edwards 2012; Li
et al. 2013; Yu et al. 2014). Mice lacking ABCG5 and ABCG8 proteins have
decreased ability to secrete sterols into the bile (Yu et al. 2002a). The
overexpression of ABCG5 and ABCG8 in the liver increases biliary cholesterol
secretion and decreases dietary cholesterol absorption (Yu et al. 2002b). The human
ABCG5 and ABCG8 genes are oriented in a head-to-head configuration, they are
transcribed in opposite directions, and their transcription is coordinated by a short
374 bp bidirectional promoter in the intergenic region (Remaley et al. 2002).
The bidirectional promoter of ABCG5/ABCG8 genes contains a binding site for
LRH-1 at positions 134–142 which is required for the activity of both the ABCG5
and ABCG8 promoters (Freeman et al. 2004). Mutating this LRH-1 binding site
reduced promoter activity of the human ABCG5/ABCG8 intergenic region in
HepG2 and Caco2 cells. Bile acids such as deoxycholic acid repressed ABCG5
and ABCG8 promoters via the FXR-SHP-LXR pathway that was described above
(Sumi et al. 2007).
Dietary cholesterol feeding was shown to increase duodenal, jejunal, and hepatic
expression levels of ABCG5 and ABCG8 mRNA in wild-type mice (Berge
et al. 2000). The increase in ABCG5 or ABCG8 gene expression by diet was
compromised in mice lacking either LXRα or both LXRα and LXRβ (Repa
et al. 2002). Both the RXR-specific agonist LG268 and the LXR-specific agonist
T0901317 caused upregulation of ABCG5 and ABCG8 mRNA expression in the
liver and intestine of wild-type mice but not in LXRα/β/ mice (Repa et al. 2002).
To identify functional LXREs that control the expression of the ABCG5/ABCG8
genes in response to oxysterols, a recent study searched for evolutionarily
conserved regions (ECRs) between the human and the mouse genes and identified
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23 ECRs which were studied by luciferase assays for LXR responsiveness (Back
et al. 2013). Two ECRs were found to be responsive to the LXR and binding of
LXRα to these regions was verified (Back et al. 2013).
The bidirectional promoter of the ABCG5/G8 genes was shown to bind HNF-4
and GATA transcription factors and to be regulated by these factors in a coopera-
tive manner and independent of the orientation of the bidirectional promoter (Sumi
et al. 2007).
It was shown that the expression of both ABCG5 and ABCG8 genes is
upregulated in the livers of mice with genetic ablation of the insulin receptor
gene (LIRKO mice) both at the mRNA and the protein levels (Biddinger
et al. 2008). In agreement with these findings, insulin suppressed the expression
of ABCG5 and ABCG8 genes at subnanomolar concentrations and in a dose-
responsive manner in rat hepatoma cells (Biddinger et al. 2008). The observation
that the short intergenic region responded to insulin in both the ABCG5 and
ABCG8 orientations suggested the presence of an element in the intragenic region
of the ABCG5 and ABCG8 genes that responds to insulin. Using ex vivo and
in vivo approaches, it was shown that insulin resistance leads to the activation of the
forkhead box 1 (FOXO1) transcription factor which binds to the bidirectional
promoter and activates the transcription of both genes severalfold (Biddinger
et al. 2008).
1.10 Transcriptional Regulation of the HDL Receptor SR-BI
The gene encoding the HDL receptor scavenger receptor class B type I (SR-BI) is
expressed at high levels in the liver and steroidogenic tissues. Several transcription
factors have been shown to bind to the human or rodent SR-BI promoter and to
regulate SR-BI gene transcription in a positive or negative manner.
The steroidogenic factor-1 (SF-1) has been shown to regulate both the human
and rat SR-BI promoters and to serve as mediator of the cAMP-dependent regu-
lation of the SR-BI gene in response to steroidogenic hormones (Lopez et al. 1999).
Liver X receptors α and β and PPARα and γ were shown to bind to distal LXRE
and PPARE, respectively, on the human and rat SR-BI promoters and regulate the
expression of the human SR-BI gene in response to oxysterols and fibrates (Lopez
and McLean 1999; Malerod et al. 2002, 2003), whereas HNF-4 enhances the
PPARγ-mediated SR-BI gene transcription (Malerod et al. 2003; Zhang
et al. 2011). As discussed above, conditional inactivation of the HNF-4 gene in
the liver of adult mice was associated with a significant increase in hepatic SR-BI
mRNA levels and a decrease in plasma HDL-C levels, suggesting that HNF-4
influences negatively the expression of the HDL receptor (Hayhurst et al. 2001).
LRH-1 binds to a proximal response element on the human SR-BI promoter in
an overlapping manner with SF-1 and activates the SR-BI promoter (Schoonjans
et al. 2002). Retrovirus-mediated overexpression of LRH-1 in hepatic cells induced
SR-BI gene expression, and this was associated with histone H3 acetylation on the
SR-BI promoter. In agreement with these findings, the SR-BI mRNA levels were
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decreased in the livers of LRH-1(+/) animals providing evidence that LRH-1
regulates SR-BI gene expression in vivo (Schoonjans et al. 2002).
Estrogens regulate the activity of the rat SR-BI promoter via estrogen receptors
α and β (ERα and β) which bind to three different estrogen response elements (ERE)
on the SR-BI promoter (Lopez et al. 2002; Lopez and McLean 2006). In endothelial
cells, 17beta-estradiol (E2) increased the mRNA levels of the human SR-BI gene
and the activity of the hSR-BI promoter, and this upregulation was protein kinase C
(PKC) dependent since it was blocked by the PKC inhibitor bisindolylmaleimide I
and a dominant-negative mutant of PKC (Fukata et al. 2013).
The mRNA levels of the mouse SR-BI gene were decreased in mice lacking the
FXR nuclear receptor (FXR/ mice) (Lambert et al. 2003). When WT mice were
placed on a diet containing 0.4 % of the FXR agonist cholic acid, the hepatic SR-BI
mRNA and protein levels increased in the wild-type but not in the FXR/ mice,
indicating that bile acids positively regulate SR-BI gene expression via FXRs
(Lambert et al. 2003). In agreement with these findings, treatment of human
hepatoma HepG2 cells with FXR ligands resulted in the upregulation of SR-BI
both at the mRNA and protein levels via FXR binding to a novel FXRE, a direct
repeat 8 at position703/684 of the promoter (Chao et al. 2010). A natural ligand
of FXR administered to mice increased hepatic SR-BI expression (Chao
et al. 2010). However, in another study, it was reported that bile acids inhibit
SR-BI gene expression in the liver of mice and reduce the SR-BI promoter activity
(Malerod et al. 2005). It was proposed that this inhibition was due to the
FXR-mediated activation of SHP, which repressed the activity of LRH-1 that
binds to the proximal SR-BI promoter (Malerod et al. 2005).
The zinc finger transcription factor Kruppel-like factor 4 (KLF4) was shown to
bind to a putative KLF4 element on the SR-BI promoter at position342/329 and
upregulate its activity in peripheral blood mononuclear cells and
PMA-differentiated THP-1 cells treated with HDL (Yang et al. 2010).
Using high-throughput screening of 6,000 microbial secondary metabolite crude
extracts for the identification of compounds that upregulate the SR-BI promoter in
HepG2 cells, several putative SR-BI upregulators were identified: hoxyl-30,5,7-
hydroxyl isoflavone; (9R,13S)-7-deoxy-13-dihydrodaunomycinone; pratensein; the
isoflavones formononetin, genistein, and daidzein; and the histone deacetylase
inhibitor trichostatin A (Yang et al. 2007, 2009; Bao et al. 2009). Some of these
compounds were shown to increase the uptake of DiI-labeled HDL and the efflux of
cholesterol to HDL by cells.
In steroidogenic tissues, SR-BI supplies the cells with exogenous cholesterol for
storage or for the synthesis of steroid hormones. In these tissues, SR-BI expression
was shown to be upregulated by adrenocorticotropic hormone (ACTH) (Sun
et al. 1999). The suppression of ACTH by the synthetic corticosteroid dexametha-
sone (which inhibits the hypothalamic-pituitary axis and decreases ACTH secre-
tion) decreased SR-BI levels. However, the mechanism by which ACTH and
glucocorticoid regulate the expression of the SR-BI gene in steroidogenic tissues
is unclear. It was shown that the transcription of the human SR-BI gene is subject to
feedback inhibition by glucocorticoids in adrenal and ovarian cells. SR-BI mRNA
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levels were increased in adrenals from corticosterone-insufficient Crh/ mice,
whereas corticosterone replacement by oral administration inhibited SR-BI gene
expression in these mice (Mavridou et al. 2010). The glucocorticoid-mediated
inhibition of SR-BI gene transcription required de novo protein synthesis and the
glucocorticoid receptor (GR). No direct binding of GR to the SR-BI promoter could
be demonstrated in vitro and in vivo, suggesting an indirect mechanism of repres-
sion of SR-BI gene transcription by GR in adrenal cells (Mavridou et al. 2010).
In the rat ovary, the uptake of cholesterol by the theca-interstitial cells is
mediated by SR-BI. It was shown that insulin and the trophic hormone LH/cGH
stimulate the expression of SR-BI in theca-interstitial cells and increase intracellu-
lar cholesterol, which is subsequently mobilized for androgen biosynthesis
(Li et al. 2001; Towns et al. 2005).
In the adrenocortical cell line Y-1, adenovirus-mediated overexpression of
prolactin regulatory element-binding (PREB) protein, a transcription factor that
regulates prolactin expression in the anterior pituitary and is induced by cAMP,
increased the levels of SR-BI protein and the activity of the SR-BI promoter by
binding to a PREB-responsive cis-element of the SR-BI promoter. Using small
interfering RNA against PREB in Y-1 cells, the effects of cAMP on SR-BI
expression were attenuated. It was concluded that in the adrenal gland under
conditions of cAMP increase, PREB regulates the transcription of the SR-BI gene
(Murao et al. 2008).
Intracellular sterol levels regulate SR-BI gene expression via SREBP-1a which
binds to two sterol-responsive elements (SREs) present on the rat SR-BI promoter
(Cao et al. 1997; Lopez and McLean 1999). The ubiquitous transcription factors
SP1 and SP3 bind to several GC-rich boxes present on the proximal SR-BI
promoter and have been shown to be important for the basal activity as well as
the SREBP-1a-mediated transactivation of the SR-BI promoter (Shea-Eaton
et al. 2001).
The expression of the SR-BI gene is also subject to negative regulation by
transcription factors including the orphan nuclear receptor dorsal-sensitive sex
adrenal hypoplasia congenital critical region on the X chromosome gene
1 (DAX-1), which was shown to repress the rat SR-BI promoter by interfering
with the SF-1- and SREBP-1a-mediated transactivation of the this promoter (Lopez
et al. 2001). In addition, YY1 transcription factor binds directly to two sites on the
SR-BI promoter and downregulates its activity by interfering with the binding of
SREBP-1a to the SR-BI promoter (Shea-Eaton et al. 2001).
2 Posttranscriptional Regulation of HDL Genes
by Noncoding RNAs and microRNAs
According to the Encyclopedia of DNA Elements (ENCODE project), 76 % of the
human genome is transcribed (Bernstein et al. 2012; Djebali et al. 2012). While
novel promoter and enhancer regions have been described (Bernstein et al. 2012;
Sanyal et al. 2012), some of the newly described genes encode for noncoding RNAs
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including microRNAs (miRNAs), small interfering RNAs (siRNAs), piwi-
interacting RNAs (piRNAs), circular RNAs (circRNAs), long noncoding RNAs
(lncRNAs), trans-acting siRNAs (tasiRNAs), and several other noncoding RNAs.
Their abundance and their recognized roles in transcriptional and epigenetic gene
regulation and their involvement in several diseases suggest the existence of an
extensive regulatory network on the basis of RNA signaling (Mattick and Makunin
2005). An important class of these endogenous noncoding RNAs is miRNAs.
miRNAs are small noncoding RNAs (~22 nt) that have emerged as important
posttranscriptional regulators of different protein-coding genes (Bartel 2009)
including those related to HDL metabolism (Davalos and Fernandez-Hernando
2013).
2.1 miRNAs: Biogenesis and Function
Although originally described as regulators of developmental timing in
Caenorhabditis elegans (Lee et al. 1993; Wightman et al. 1993), miRNAs did not
receive special attention until their widespread identification in different species
(Lagos-Quintana et al. 2002; Reinhart et al. 2002) and their role in human diseases
was uncovered (Calin et al. 2002). miRNAs are important posttranscriptional
regulators of gene expression through sequence-specific complementary binding
to the 30 untranslated region (UTR) of the target mRNA (Bartel 2009), even though
certain miRNAs can interact with other target mRNA regions including the 50 UTR,
coding region, or intron–exon junction and even increase rather than decrease target
mRNA expression (Vasudevan et al. 2007; Orom et al. 2008; Tay et al. 2008;
Schnall-Levin et al. 2010). The interaction of a miRNA with its target mRNA
results in the inhibition of translation and/or degradation of mRNAs (Guo
et al. 2010; Krol et al. 2010).
miRNA biogenesis and function have been intensively studied in recent years
(Bartel 2009; Krol et al. 2010). Briefly, in most mammals, these small RNAs are
transcribed by RNA polymerase II into a primary long miRNA (pri-miRNA). The
pri-miRNA is then processed in the nucleus into an ~70 nucleotide precursor
hairpin (pre-miRNA) by a multiprotein complex containing different cofactors
and two core components, a ribonuclease III (Drosha) and a double-stranded
RNA-binding domain protein (DGCR8/Pasha). Some intronic miRNAs that bypass
Drosha-mediated processing are produced by splicing and debranching (miRtrons).
Pre-miRNAs are transported to the cytoplasm by Exportin 5 in a Ran-GTP-depen-
dent manner (Lund et al. 2004) where they are further cleaved by an RNAse III
enzyme called Dicer, generating the mature ~22 nt long miRNA/miRNA* duplex.
Dicer-independent miRNA biogenesis has also been described (Cifuentes
et al. 2010). The duplex miRNA is separated and one of the strands associates
with an argonaute protein (Ago) within the RNA-induced silencing complex
(RISC), guiding the complex to the complementary sites within the 30 UTR of the
target mRNA to induce mRNA repression and/or degradation. Although the
miRNA/miRNA* duplex is initially produced in equal amounts, the miRNA*
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strand (passenger strand) is usually degraded. However, it also contains target
recognition sites and is thus functional (Yang et al. 2011). Argonaute proteins are
major players in miRNA-mediated gene regulation (Meister 2013). Although
several aspects of miRNA biogenesis and function are well characterized, the
different factors that regulate their decay or turnover are not well known (Krol
et al. 2010).
Sequencing studies have identified ~2,000 miRNAs encoded in our human
genome, and prediction algorithms suggest that 60 % of human protein-coding
genes have conserved targets for pairing with miRNAs within their 30 UTR
(Friedman et al. 2009). Factors that influence miRNA target selection include the
“seed” sequence which consists of nucleotides 2–8 at the 50 end of the mature
miRNA (Bartel 2009) and tissue distribution or developmental stage, as certain
miRNAs are highly expressed or even restricted to certain cell types and can only
target their mRNA target if they are co-expressed in the same tissue at the same
time (Lagos-Quintana et al. 2002; Small and Olson 2011). In contrast to most plant
miRNAs, which bind with near perfect complementarity to their targets, most
mammalian miRNAs bind with mismatches and bulges and the mode of binding
determines the type of posttranscriptional repression (Carthew and Sontheimer
2009). Recent experimental data suggest that around 60 % of seed interactions
are noncanonical, containing bulged or mismatched nucleotides which are
accompanied by specific, non-seed base pairing (Helwak et al. 2013). Some
miRNA-mRNA interactions also involve the 30 end of the miRNA (Helwak
et al. 2013). Moreover, pseudogenes (Poliseno et al. 2010), long noncoding
RNAs (lncRNAs) (Cesana et al. 2011), and circular RNAs (Hansen et al. 2013)
that contain miRNA binding sites also influence miRNA activity, acting as com-
peting endogenous RNAs (ceRNAs) and thus sequestering miRNAs and preventing
them from binding to their mRNA targets (Salmena et al. 2011).
While the primary role of miRNAs seems to be the “fine-tuning” of gene
expression, their capacity to simultaneously bind and repress multiple target
genes and similarly the possibility of a single mRNA to be targeted by multiple
miRNAs provide a mechanism to synchronize the coordinated regulation of a large
number of transcripts that govern an entire biological process, thus resulting in
strong phenotypic output (Mendell and Olson 2012). The high redundancy among
related and non-related miRNAs in regulating gene expression reduces the impor-
tance of a particular miRNA under conditions of normal cellular homeostasis.
However, compelling evidence suggests that under conditions of stress the function
of miRNAs become especially pronounced (Mendell and Olson 2012) and their
pharmacological modulation represents a novel approach to treat disease by
modulating entire biological pathways as described in Davalos and Chroni (2014).
Compelling evidences have shown that miRNAs are present in the systemic
circulation and other human biological fluids associate with extracellular
microvesicles, exosomes (Valadi et al. 2007; Hunter et al. 2008), Ago2 complex
(Arroyo et al. 2011), or HDL (Vickers et al. 2011). Even exogenous miRNAs have
been described in our circulating plasma (Wang et al. 2012b; Zhang et al. 2012).
Although several circulating miRNAs have been implicated as disease biomarkers
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in several diseases (Allegra et al. 2012; Kinet et al. 2013) or secreted for intercellu-
lar communication (Chen et al. 2012b), the biological significance, the factors that
modulate their extracellular secretion, and the mechanisms by which they reach the
target tissue still remain elusive. HDL has been shown to transport and deliver
endogenous miRNAs to recipient cells with functional targeting capabilities
(Vickers et al. 2011). Although the HDL miRNA signature from normal subjects
was found to be different from hypercholesterolemic subjects (Vickers et al. 2011),
the extent by which HDL-bound miRNAs contribute to total circulating miRNAs
and thus regulate target cell gene function is not clear (Wagner et al. 2013).
In summary, miRNAs play a major role in almost every aspect of cellular
function by posttranscriptional regulation of gene expression. Whether other non-
coding RNAs (that modulate miRNA activity) or circulating or extracellular
miRNAs might modulate HDL metabolism is not known. However, it seems
obvious that by modulating miRNA activity, they might also have a role in HDL
metabolism.
2.2 Posttranscriptional Modulation of HDL Metabolism
by miRNAs
For normal function, mammalian cells must maintain cellular cholesterol levels
within tight limits. Thus, complex mechanisms have been evolutionarily developed
to control both cellular input from endogenous cholesterol biosynthesis or the
uptake from circulating lipoproteins and cellular output by controlling cholesterol
efflux. miRNAs have emerged as important regulators of HDL and cholesterol
metabolism, and their functions are summarized in Fig. 5 and described in detail
below. Although miRNAs have increased the complexity of HDL metabolism
regulation, our understanding of every single step in their regulation will provide
better opportunities to develop novel targets for their therapeutic modulation.
2.2.1 Targeting ABCA1 and ABCG1
ABCA1 is one of the most important proteins directly involved in the elimination of
excess cholesterol from cells (cholesterol efflux). As described in this chapter,
ABCA1 is regulated at the transcriptional, posttranscriptional, and posttranslational
level. Its regulation is in accordance with the cellular need to handle cholesterol
levels within tight limits, as excess of free cholesterol is deleterious to cells.
ABCA1 mRNA contains a particularly long 30 UTR (>3.3 kb) as compared to
other common genes involved in cholesterol and HDLmetabolism including LCAT
(20 bp), apoA-I (55 bp), ApoA-II (112 bp), CETP (178 bp), apoB (301 bp), PDZK1
(583 bp), ABCG1 (852 bp), SR-BI (959 bp), PCSK9 (1,269 bp), IDOL (1,496 bp),
CAV-1 (1,898 bp), LIPG (2,386 bp), and LDLR (2,513 bp) (Davalos and
Fernandez-Hernando 2013). This unusually long 30 UTR of ABCA1 clearly raises
the probability of posttranscriptional regulation by miRNAs (and probably other
noncoding RNAs). Different prediction algorithms indicate that ABCA1 can poten-
tially be targeted by ~100 miRs. Some of them have been experimentally validated
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Fig. 5 Overview of posttranscriptional regulation by miRNAs of proteins involved in cholesterol
efflux, RCT, and HDL metabolism. HDL metabolism and the role of individual proteins such as
plasma enzymes, membrane transporters, and receptors are described in the text and more
extensively in other chapters. Autophagy, the cell catabolism process through the lysosomal
machinery, has been proposed to participate in cholesterol efflux. The induction of SREBPs
induces the expression of miR-33 family. The induction of LXR induces the expression of
miR-144 and represses miR-26. The induction of FXR also induces miR-144. miRNAs in black
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for their importance in cholesterol efflux, reverse cholesterol transport, and cardio-
vascular disease, whereas other miRNAs still remain to be elucidated. Validated
miRNAs that directly target ABCA1 are miR-33 family, miR-758, miR-106b,
miR-26, miR-144, miR-10b, miR-128-2, and miR-145 (Fig. 5).
miR-33a and miR-33b play a crucial role in controlling cholesterol efflux and
HDL function in concert with their host genes, the SREBP transcription factors
(Najafi-Shoushtari et al. 2010; Horton et al. 2002; Horie et al. 2010; Marquart
et al. 2010; Rayner et al. 2010). While both mature miRNAs only differ in two
nucleotides, they are predicted to have largely overlapping sets of target genes in
rodents (Rayner et al. 2011b; Horie et al. 2012) and nonhuman primates (Rayner
et al. 2011a; Rottiers et al. 2013). The inhibition of the two miR-33 isoforms, either
genetically or therapeutically, resulted in increased cholesterol efflux, increased
HDL levels, increased reverse cholesterol transport, reduced atherosclerosis, and
reduced VLDL triglyceride levels. Although miR-33a and miR-33b target different
genes involved in lipid homeostasis, fatty acid β-oxidation, insulin signaling, and
biliary transporters (Gerin et al. 2010; Davalos et al. 2011; Rayner et al. 2011a;
Allen et al. 2012; Horie et al. 2013), their effects are mediated mainly by ABCA1.
The human 30 UTR of ABCA1 has three functional binding sites for miR-33. While
most of the studies have been performed in tissues/cells directly related to lipo-
protein metabolism and CVD (i.e., hepatocytes, macrophages), it is possible that
from these ~100 miRs that potentially target ABCA1 30 UTR, some of them might
be relevant to other cells and tissues as well.
Regarding other tissues, miR-106b (Kim et al. 2012) and miR-758 (Ramirez
et al. 2011) were found to regulate neuronal cholesterol excess. While miR-758
expression is particularly high in the brain and its expression is mediated by high
cholesterol levels, the expression of miR-106 in brain tissues is low. However, their
role in neuronal cholesterol efflux suggests that these miRNAs may contribute to
the regulation of cholesterol levels in the brain. miR-758 and miR-106 directly
target the 30 UTR of ABCA1 by binding to two sites and one site, respectively.
Moreover, miR-758 has other targets involved in neurological functions (Ramirez
et al. 2011). miR-106b also targets the amyloid precursor protein (APP) and
increases the amyloid β (Aβ) peptide secretion and clearance (Kim et al. 2012).
HDL metabolism is regulated by the LXRs which control the transcription of
several genes related to lipid metabolism in response to hydroxylated products of
cholesterol as described above (Calkin and Tontonoz 2012). Recent data suggest
that LXRs also regulate HDL metabolism posttranscriptionally (Sun et al. 2012; de
Aguiar Vallim et al. 2013; Ramirez et al. 2013; Vickers and Rader 2013). The
induction of LXR resulted in the repression of miR-26 and induction of miR-26-a-1,

Fig. 5 (continued) labels are validated miRNAs for HDL metabolism. miRNAs in red labels are
suggested miRNAs, but not fully validated, in HDL metabolism. All biological processes may not
necessarily happen in the same cell type. Abbreviations: endoplasmic reticulum (ER); early
endosome (EE); cholesterol ester hydrolase (CEH); multivesicular bodies (MVB); lysosomal
acid lipase (LAL) (Figure courtesy of Dr. Alberto Canfra´n-Duque)
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and miR-144 that directly target the 30 UTR of ABCA1 and thus regulate choles-
terol efflux, RCT, and HDL levels. While having one binding site for miR-26-a-1
(Sun et al. 2012), the human 30 UTR of ABCA1 has several (up to seven) predicted
binding sites for miR-144 (Ramirez et al. 2013). miR-26-a-1 also targets the
ADP-ribosylation factor-like 7 (Arl7), which participates in cellular cholesterol
efflux (Engel et al. 2004). miR-144 expression is also induced by the nuclear
receptor FXR (Vickers and Rader 2013). By controlling bile acid levels, FXR
activation will not only repress the expression of ABCA1 posttranscriptionally
but will also induce the expression of SR-BI, thereby resulting in an increased
uptake of plasma HDL cholesterol and increased cholesterol biliary excretion via
ABCG5/ABCG8 (de Aguiar Vallim et al. 2013).
Evolutionarily, the dual effect of LXR activation on miR-144 induction and
mR-26-a-1 repression seems obvious, as cells must maintain cellular cholesterol
levels within tight limits and these miRNAs might work as buffers against deleteri-
ous variation in gene expression programs.
Other miRNAs including miR-10b, miR-128-2, and miR-145 also regulate
cellular cholesterol efflux by directly targeting the 30 UTR of ABCA1.
Protocatechuic acid, an intestinal microbiota metabolite of cyanidin-3-O-glucoside,
was found to repress miR-10b and thus regulate cholesterol efflux (Wang
et al. 2012a). While in hepatocytes the inhibition of miR145 increases cholesterol
efflux, in pancreatic islet beta cells it improves glucose-stimulated insulin secretion
(Kang et al. 2013). The proapoptotic miRNA miR-128-2 was also found to regulate
cholesterol efflux by targeting (one binding site) the 30 UTR of ABCA1 (Adlakha
et al. 2013). Recent data suggest that this miRNA family governs neuronal
excitability and motor behavior in mice (Tan et al. 2013) and that miR-128-
2 might control neuronal cholesterol levels. RXRα is also a direct target of
miR-128-2 (Adlakha et al. 2013). miR-27a and miR-148 were found to repress an
ABCA1 30 UTR luciferase reporter construct; however, their physiological role in
regulating cholesterol efflux has not been described (Kang et al. 2013).
ABCG1, the other member of the ATP-binding cassette transporter family,
which also participates in cellular cholesterol efflux to HDL, was found to be
directly regulated by some of these miRNAs. miR-33, miR-10b, and miR-128-
2 regulate cholesterol efflux by posttranscriptionally regulating ABCG1 through
binding to its 30 UTR (Rayner et al. 2010; Wang et al. 2012a; Adlakha et al. 2013).
2.2.2 Targeting SR-BI
Liver regulation of SR-BI is primarily achieved posttranslationally through a PDZ
domain-containing adaptor protein (PDZK1) (Kocher et al. 2003; Kocher and
Krieger 2009) as described in detail in a later section of this chapter. Increasing
evidence suggests that other posttranscriptional mechanisms, such as targeting by
miRNAs, also regulate SR-BI protein levels. Prediction miRNA analysis (www.
targetscan.org) suggests that ~25 miRNA families might target SR-BI, most of
which are poorly conserved among mammals and vertebrates. miR-125a and
miR-455 were found to repress the lipoprotein-supported steroidogenesis by
directly targeting the 30 UTR of SR-BI (Hu et al. 2012). In hepatic cells, where
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SR-BI is expressed at higher levels, the expression of miR-125a was also high and
its overexpression resulted in a reduced SR-BI-mediated selective cholesterol ester
uptake. In contrast, miR-455 did not show any effect on hepatic SR-BI expression
(Hu et al. 2012). miR-185, miR-96, and miR-223 were also found to directly target
the 30 UTR of SR-BI and to repress HDL cholesterol uptake in hepatic cells (Wang
et al. 2013a).
2.2.3 Targeting Other miRNAs Related to HDL Biogenesis
and Function
miR-27a was suggested to regulate apoA-I plasma levels, but the direct interaction
to its 30 UTR was not evaluated (Shirasaki et al. 2013). Several other miRNAs were
proposed to regulate genes involved in cholesterol efflux, RCT, or HDL meta-
bolism, including ABCG5 (Liu et al. 2012) or endothelial lipase (Kulyte et al. 2013),
but either their direct interaction with the 30 UTR of these genes or their physio-
logical effects on HDL metabolism were not directly assessed.
Autophagy is the catabolic process by which unnecessary or dysfunctional
cellular components are degraded in the lysosome. During starvation, this break-
down of cellular components contributes to the maintenance of cellular energy
levels. The hydrolysis of cytoplasmic cholesteryl ester of lipid droplets is normally
mediated by the action of neutral cholesteryl ester hydrolases. It has been recently
recognized that lipid droplets can also be delivered to lysosomes via autophagy,
where lysosomal acid lipase can hydrolyze lipid droplet cholesteryl esters to
generate free cholesterol for cholesterol efflux (Ouimet et al. 2011).
Several miRNAs have been described that regulate different targets in
autophagy (Frankel and Lund 2012). miRNAs that target key pathways in lipid-
loaded macrophage autophagy genes and/or cholesterol ester hydrolases might be
promising targets to promote cholesterol efflux (Davalos and Fernandez-Hernando
2013). Caveolin, the major protein coat of caveolae, has been proposed to contri-
bute to cellular cholesterol efflux (Truong et al. 2010; Kuo et al. 2011). There is
accumulating evidence that several miRNAs including miR-103, miR-107,
miR-133a, miR-192, miR-802, and others target caveolin (Nohata et al. 2011;
Trajkovski et al. 2011) but their contribution to cholesterol efflux, RCT, and
HDL metabolism and their real physiological contribution to HDL function remain
to be elucidated.
3 Posttranslational Mechanisms of HDL Regulation
3.1 ABCA1
In addition to the transcriptional and posttranscriptional mechanisms described
above, the expression of ABCA1 is also regulated at the posttranslational level.
Following its synthesis, ABCA1 is inserted into the ER where it undergoes proper
folding, N-glycosylation, dimerization, and disulfide bond formation and transport
to the plasma membrane via the ER-Golgi system (Fig. 6) (Kang et al. 2010).
150 D. Kardassis et al.
Transport from the ER to the Golgi is prevented when ABCA1 interacts with the
enzyme serine palmitoyltransferase 1 (SPTLC1) which participates in the biosyn-
thetic pathway of sphingomyelin, a major phospholipid component of membranes.
The ABCA1/SCPTL1 interaction may regulate the levels of intracellular pools of
sphingolipids when the cellular demands for these lipids are high. Pharmacological
inhibition of SPTLC1 with myriocin, an atypical amino acid and antibiotic derived
from thermophilic fungi (Miyake et al. 1995), increases both the ABCA1 levels at
the plasma membrane and the ABCA1-mediated cholesterol efflux (Tamehiro
et al. 2008). Mutations in ABCA1 that prevent normal glycosylation cause failure
Fig. 6 Overview of the mechanisms that regulate the expression of ABCA1, ABCG1, and SR-BI
genes at the posttranslational level. The mechanisms are described in the text. Abbreviations:
endoplasmic reticulum (ER); Asp-His-His-Cys 8 (DHHC8); serine palmitoyltransferase
1 (SPTLC1); guanine nucleotide-exchange protein 1 (BIG1); endosomal sorting complex required
for transport (ESCRT); Pro-GLu-Ser-Thr (PEST); calmodulin (Cam); lymphotoxin (LT); LT-β
receptor (LTβR); phospholipase D (PLD); protein kinase C δ (PKCδ); insulin receptor (IR);
phosphatidylinositol 3-kinase (PI3K); 12/15-lipoxygenase (12/15LO); PDZ-containing kidney
protein 1 (PDZK1); Na+/H+ exchanger regulator factor-3 (NHERF3); 4-hydroxy-2-nonenal
(4HNE); monocyte chemoattractant protein-1 (MCP-1)
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of ABCA1 to exit the ER (Singaraja et al. 2006). In the Golgi compartment,
ABCA1 undergoes palmitoylation at cysteine residues 3, 23, 1110, and 1111 by
the palmitoyltransferase Asp-His-His-Cys 8 (DHHC8) (Singaraja et al. 2009).
Inhibiting this enzyme by drugs or preventing ABCA1 palmitoylation by site-
specific mutagenesis reduced ABCA1 levels at the plasma membrane and
decreased efflux to apoA-I (Singaraja et al. 2009). The gene encoding
cathepsin D, a lysosomal protease, was identified by comparative transcriptomic
analysis to be associated with low HDL-C levels in humans (Haidar et al. 2006).
Blocking the activity or expression of cathepsin D reduced ABCA1 expression and
protein abundance as well as apoA-I-mediated lipid efflux by more than 70 % and
caused retention of ABCA1 in lysosomal compartments (Haidar et al. 2006). Very
recently, BIG1 (brefeldin A-inhibited guanine nucleotide-exchange protein 1) was
found to modulate ABCA1 trafficking and functions in the liver cells (Lin
et al. 2013). BIG1 depletion reduced surface ABCA1 on HepG2 cells and inhibited
by 60 % cholesterol efflux, whereas BIG1 overexpression had the opposite effects.
RNA interference with BIG1 dramatically decreased the internalization and
recycling of ABCA1. This novel function of BIG1 was dependent on the
guanine nucleotide-exchange activity and achieved through the activation of
ADP-ribosylation factor 1 (Lin et al. 2013).
The transport of ABCA1 to the plasma membrane is also facilitated by certain
members of the family of small GTPase including Rab8, Rab4A, and Rab4B
(Linder et al. 2009) (Jean and Kiger 2012).
Calpain, a cysteine protease, cleaves ABCA1 at the PEST (proline, glutamic
acid, serine, threonine) sequence (amino acids 1283–1306) that is located in the
cytosolic loop of the molecule, and this cleavage takes place at the early endosomes
(Fig. 6) (Yokoyama et al. 2012; Miyazaki et al. 2013). The deletion of the PEST
sequence increases ABCA1 levels on the plasma membrane and apoA-I binding
(Chen et al. 2005). The interaction with apoA-I stabilizes ABCA1 against this
degradation (Arakawa and Yokoyama 2002; Wang et al. 2003; Arakawa
et al. 2004). Importantly, the inhibition of calpain was shown to increase HDL
biogenesis in cultured cells, indicating that the inhibition of proteolytic degradation
of ABCA1 could be a promising strategy for increasing HDL (Lu et al. 2008). The
phosphorylation of the PEST sequence of ABCA1 at Thr-1286 and Thr-1305
regulates calpain-mediated proteolysis of ABCA1 since the ABCA1-T1286A/
T1305A mutant could not be degraded by calpain (Martinez et al. 2003). The
interaction of ABCA1 with apoA-I results in the dephosphorylation of the
ABCA1 PEST sequence and inhibition of calpain degradation, leading to an
increase of ABCA1 cell-surface expression (Martinez et al. 2003). Calmodulin
was also shown to interact with ABCA1 in the presence of Ca2+ and to protect
from calpain-mediated degradation (Iwamoto et al. 2010).
In addition to the calpain-mediated proteolytic degradation of ABCA1 described
above, ABCA1 is subject to ubiquitin-mediated proteolysis. The presence of
ubiquitinated ABCA1 in the plasma membrane of several cell lines was recently
demonstrated (Mizuno et al. 2011). In HuH-7 cells, the degradation of cell-surface-
resident ABCA1 was inhibited by the overexpression of a dominant-negative form
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of ubiquitin. Moreover, the disruption of the endosomal sorting complex required
for transport (ESCRT) pathway by the knockdown of hepatocyte growth factor-
regulated tyrosine kinase substrate (HRS) delayed the degradation of ABCA1
(Mizuno et al. 2011). These findings suggested that ubiquitination mediates the
lysosomal degradation of plasma membrane ABCA1 and thereby regulates the
expression and cholesterol efflux functions of ABCA1 independently of the
calpain-mediated pathway.
Unsaturated fatty acids such as oleate and linoleate were shown to destabilize
ABCA1 protein and to inhibit ABCA1-mediated cholesterol efflux in macrophages
by a mechanism that depends on the activity of the enzyme acyl-CoA synthetase
1 which is responsible for their activation to their CoA derivatives (Kanter
et al. 2012). At the same time, unsaturated fatty acids increase the Ser phosphory-
lation of ABCA1 via a phospholipase D (PLD)/protein kinase C δ pathway which
contributes to ABCA1 destabilization (Fig. 6) (Wang and Oram 2007).
Two additional proteins that were identified by two-hybrid screen to physically
interact with ABCA1 and to regulate ABCA1 intracellular localization and turnover
by interacting with its PDZ (PSD-95, Dlg, ZO-1) domain are the a1 and b1
syntrophins (Munehira et al. 2004). Given the short half-life of ABCA1
(t1/2 ¼ 1–2 h) (Wang et al. 2003), interfering with the accessory proteins or the
enzymes that posttranslationally modify ABCA1 may prove a valuable strategy to
regulate ABCA1-mediated HDL biogenesis in the liver and the intestine or to
enhance cholesterol efflux in peripheral cells.
Insulin enhances ABCA1 protein degradation in HepG2 cells via PI3K.
In addition, it inhibits ABCA1 activity by phosphorylation at Tyr1206 (Nonomura
et al. 2011). The kinase that is responsible for this Tyr phosphorylation of ABCA1
is not known, but it was hypothesized that it is the insulin receptor itself.
TNFα and lymphotoxin α (LT) are key inflammatory mediators which also
contribute to the atherogenic process (Schreyer et al. 1996, 2002; Pamir
et al. 2012). TNF induces ABCA1 mRNA and protein levels as well as cholesterol
efflux from cultured macrophages to apoA-I (Gerbod-Giannone et al. 2006). The
induction of ABCA1 by TNFα depended primarily on NF-κB (Gerbod-Giannone
et al. 2006). It was also shown that the expression of the two TNF receptors is
required to mediate full ABCA1 induction by TNFα. In addition, LT increased
ABCA1 protein levels by inhibiting protein degradation through the LT-β receptor
(LTβR) (Edgel et al. 2010).
ABCA1-mediated cholesterol efflux and ABCA1 protein levels were shown to
be decreased by interferon γ (IFNγ) in murine macrophages and macrophage-
derived foam cells (Panousis and Zuckerman 2000). This ABCA1 downregulation
was an early event in IFNγ-mediated activation of macrophages (Alfaro Leon
et al. 2005) and was dependent on signal transducer and activator of transcription
1 (STAT1) since similar effects were not observed in macrophages from STAT1
KO mice (Wang et al. 2002).
Additional protein kinases were shown to affect the activity and stability of
ABCA1 at the posttranslational level including protein kinase A (PKA), protein
kinase C (PKC), Janus kinase 2 (JAK2), and casein kinase (CK2) (Tang et al. 2004).
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ABCA1 activity was shown to be regulated by the nuclear receptor LXRβ by a
mechanism that is distinct from the transcriptional induction of the ABCA1 gene
caused by cholesterol accumulation. It was shown that at low cholesterol levels,
LXRβ binds to ABCA1 and the ABCA1-LXRβ complex is stably localized at the
plasma membrane but is unable to facilitate apoA-I-mediated cholesterol efflux.
Exogenously added LXR ligands, which mimic cholesterol accumulation, cause
LXRβ to dissociate from ABCA1, thus freeing ABCA1 for apoA-I binding and
subsequent cholesterol efflux (Hozoji et al. 2008; Hozoji-Inada et al. 2011).
3.2 ABCG1
Similar to ABCA1, the levels of ABCG1 transporter were shown to be subject to
regulation at the posttranslational level (Fig. 6) (Tarling and Edwards 2012). Recent
studies showed that the presence of additional 12 amino acids between the Walker
B motif and the first transmembrane domain of ABCG1 can affect ABCG1 protein
stability (Engel et al. 2006). It was shown that stable overexpression of 12/15-
lipoxygenase (12/15LO) in macrophages was associated with a 30 % reduction in
HDL-mediated cholesterol efflux and reduced ABCG1 protein expression (Nagelin
et al. 2008). Treatment of macrophages with the 12/15LO eicosanoid product
12SHETE increased serine phosphorylation of ABCG1 and affected the stability
of the protein (Nagelin et al. 2008). Proteasomal inhibitors blocked the
downregulation of ABCG1 and resulted in the accumulation of phosphorylated
ABCG1 (Nagelin et al. 2009). Macrophages that lack 12/15LO had enhanced
ABCG1 expression, reduced ABCG1 phosphorylation, and increased cholesterol
efflux. Conversely, macrophages that overexpress 12/15LO have reduced ABCG1
expression, increased transporter phosphorylation, and reduced cholesterol efflux
(Nagelin et al. 2009). It was also shown that 12/15LO regulates ABCG1 expression
and function through p38- and JNK2-dependent mechanisms (Nagelin et al. 2009).
The activation of adenosine monophosphate-activated protein kinase (AMPK) in
human aortic endothelial cells resulted in increased levels of ABCG1 protein via a
posttranscriptional mechanism that involved increased stability of ABCG1 mRNA
(Li et al. 2010a, b). The aminoimidazole carboxamide ribonucleotide (AICAR)-
dependent induction of ABCG1 was associated with increased efflux of cellular
cholesterol and 7-ketocholesterol to HDL and protected nitric oxide synthase
activity and vascular reactivity (Li et al. 2010a, b).
The protein levels of ABCG1 were shown to be controlled by palmitoylation in
both human embryonic kidney 293 cells and in mouse macrophage, J774
(Gu et al. 2013). Five cysteine residues located at positions 26, 150, 311, 390,
and 402 in the NH2-terminal cytoplasmic region of ABCG1 were shown to be
palmitoylated. The removal of palmitoylation at Cys311 by mutating the residue to
Ala (C311A) or Ser significantly decreased ABCG1-mediated cholesterol efflux.
On the other hand, the removal of palmitoylation at sites 26, 150, 390, and 402 had
no significant effect (Gu et al. 2013).
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3.3 SR-BI
The stability of the HDL receptor SR-BI in the hepatocyte plasma membrane is
very important for its functions and is subject to posttranscriptional regulation
(Fig. 6). SR-BI stability is primarily controlled by its adapter protein,
PDZ-containing kidney protein 1 (PDZK1 or NHERF3 for Na+/H+ exchanger
regulator factor-3), since PZK1-knockout mice exhibit a >95 % reduction in
hepatic SR-BI protein (but not mRNA) and are characterized by hypercholesterol-
emia and the presence of large cholesterol-rich HDL particles in the plasma
(Kocher et al. 2003). In adrenal cells where the PDZK1 levels are very low,
additional members of the NHERF family such as NHERF1 and NHERF2 (but
not NHERF4) were shown to specifically interact with SR-BI and reduce its protein
levels (Hu et al. 2013). The data showed that the downregulation of SR-BI by these
NHERF1/2 factors significantly inhibits both HDL-CE uptake and steroid hormone
production by adrenal cells. It was concluded that the PDZK1 homologues act as
physiological translational/posttranslational regulators of the functional expression
of SR-BI (Hu et al. 2013).
Feeding mice with an atherogenic diet was accompanied by a threefold post-
translational downregulation of hepatic SR-BI at the protein level (Niemeier
et al. 2009). A similar SR-BI downregulation was observed in transgenic mice
overexpressing SREBP-1a and SREBP-1c on chow diet, and it was associated with
a decrease in the expression levels of PDZK1 (Niemeier et al. 2009).
The levels of SR-BI protein were shown to be affected in two syndromes: the
nephrotic syndrome and the Rett syndrome. It was shown that animals with
nephrotic syndrome which is characterized by dyslipidemia, impaired high-density
lipoprotein (HDL)-mediated reverse cholesterol transport, and atherosclerosis
(Vaziri et al. 2003) exhibited severe hypercholesterolemia, hypertriglyceridemia,
reduced HDL/total cholesterol ratio, significant upregulation of the endocytic HDL
receptor ATP synthase mRNA and protein, and significant reduction of SR-BI
protein despite its normal mRNA abundance. The reduction in SR-BI protein levels
in animals with NS was accompanied by parallel reductions in PDZK1 mRNA and
protein levels (Vaziri et al. 2011). Rett syndrome, a genetic form of infantile autism,
is the second most common cause of mental retardation in women (Amir
et al. 1999). When compared to healthy subjects, patients with Rett syndrome
present with significant increases in total cholesterol (12 %), LDL cholesterol
(15 %), and HDL-C (18 %) (Sticozzi et al. 2013). Skin fibroblasts isolated from
patients with Rett syndrome exhibited low levels of SR-BI as a consequence of its
association with 4-hydroxy-2-nonenal (4HNE), a product of lipid peroxidation that
is increased in patients with Rett syndrome, and increased ubiquitination (Sticozzi
et al. 2013). The role of the proteasome in SR-BI stability was confirmed using the
proteasomal inhibitor (MG132). When Rett syndrome fibroblasts were pretreated
with MG132, the loss of SR-BI was reversed demonstrating that SR-BI is degraded
via the proteasome machinery (Sticozzi et al. 2013).
In hepatic cells and fibroblasts, SR-BI protein levels and SR-BI-mediated cho-
lesterol transport (export and uptake) were shown to be affected by the Ras/MEK/
ERK signaling cascade. This effect was mediated via PPARα-inducible
Regulation of HDL Genes: Transcriptional, Posttranscriptional, and. . . 155
degradation pathways (Wood et al. 2011). Metabolic labeling experiments in
primary hepatocytes from mice demonstrated that fenofibrate enhances the degra-
dation of SR-BI in a post-endoplasmic reticulum compartment (Lan and Silver
2005). Moreover, fenofibrate-induced degradation of SR-BI was independent of the
proteasome, the calpain protease, or the lysosome (Lan and Silver 2005).
In primary macrophages and cell lines derived from female but not from male
mice, tamoxifen and 4-hydroxytamoxifen increased SR-BI protein expression via
the estrogen receptor α (Dong et al. 2011). Because SR-BI mRNA expression and
promoter activity were not influenced by tamoxifen and 4-hydroxytamoxifen, it was
demonstrated that the regulation of SR-BI by these substances takes place at the
level of protein stability (Dong et al. 2011).
The phosphatidylinositol 3-kinase (PI3K) pathway was shown to affect posi-
tively the SR-BI-mediated HDL selective cholesterol ester uptake into human
HepG2 cells as this process was compromised in the presence of the PI3K inhibitors
wortmannin and LY294002 (Shetty et al. 2006). These inhibitors also blocked the
positive effect of insulin on the SR-BI-dependent selective uptake. HDL cell-
surface binding, receptor biotinylation studies, and confocal fluorescence micro-
scopy of HepG2 cells expressing green fluorescent protein-tagged SR-BI
demonstrated changes in SR-BI subcellular localization and cell-surface expression
as a result of PI3K activation (Shetty et al. 2006). These data indicate that PI3K
activation stimulates hepatic SR-BI function posttranslationally by regulating the
subcellular localization of SR-BI. It was recently shown that monocyte chemo-
attractant protein-1 (MCP-1), a protein expressed by endothelial cells under inflam-
matory conditions, decreases the cell-surface protein expression of ABCA1,
ABCG1, and SR-BI in a dose-dependent and time-dependent manner (Huang
et al. 2013). It was shown that PI3K activation corrected the MCP-1-induced
decreases in the cell-surface protein expression of the three transporters. MCP-1
decreased the lipid uptake by HepG2 cells and the ABCA1-mediated cholesterol
efflux to apoA-I, and this was reversed by the activation of PI3K. These data
suggested that MCP-1 impairs RCT activity in HepG2 cells by a PI3K-/AKT-
mediated posttranslational regulation of ABCA1, ABCG1, and SR-BI cell-surface
expression (Huang et al. 2013).
Finally, it was shown that hormones such as triiodothyronine (T3) and
thyromimetics and some pharmacological agents such as probucol increase SR-BI
levels posttranscriptionally (Leiva et al. 2011).
Conclusions
As discussed earlier in this chapter as well as in other chapters of this handbook,
plasma HDL cholesterol levels are determined by the relative rates of HDL
biogenesis and HDL catabolism which in turn are mediated by several lipid-
carrying proteins, plasma enzymes, and membrane transporters. The deregu-
lation of the activity or the expression of these proteins by mutations or during
diseases is associated with non-physiological levels of HDL cholesterol, HDL
dysfunction, and predisposition to coronary heart disease. Epidemiological
studies as well as experiments in genetically modified animals have provided
unequivocal proof that raising HDL cholesterol levels may be therapeutic. Drugs
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that could specifically increase the rates of HDL biogenesis by inducing the
levels of apoA-I, ABCA1, or LCAT are anticipated to be of great clinical benefit.
Other HDL proteins such as ABCG1, ABCG5/G8, CETP, and LPL could also
provide useful targets for HDL-based therapies that will interfere with HDL
maturation or catabolism without compromising HDL functionality. The devel-
opment of novel HDL-raising drugs that will capitalize on HDL biogenesis will
certainly require a thorough understanding of the mechanisms and the molecules
that are involved in HDL regulation at the transcriptional, posttranscriptional, or
posttranslational level in hepatic cells as well as in other physiologically relevant
cells such as the macrophages. For instance, understanding ABCA1 gene regu-
lation in the macrophage has led to the elucidation of the important role of LXRs
and their ligands in the reverse cholesterol transport and the development of
novel LXR ligands which however have severe lipogenic effects in the liver and
are thus of no clinical value today so the challenge here is to develop more
specific drugs that will avoid lipogenesis. Novel single- or dual-specificity
agonists of peroxisome proliferator-activated receptor isoforms are also
anticipated. Understanding how the levels of HDL proteins and their functional-
ity are affected by inflammatory factors will enable us to develop novel drugs to
restore HDL levels and functionality and thus reduce the atherosclerotic burden
in patients with chronic inflammatory diseases.
In summary, the current challenges in the HDL field are to develop novel
therapies that would raise HDL cholesterol levels without compromising HDL
functionality and to identify novel HDL-based biomarkers. The advances in the
field of HDL regulation may provide crucial insights and tools to achieve
this goal.
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